id	sid	tid	token	lemma	pos
ajlm-823	1	1	abstract	abstract	ADJ
ajlm-823	1	2	introduction	introduction	NOUN
ajlm-823	1	3	methods	method	NOUN
ajlm-823	1	4	results	result	VERB
ajlm-823	1	5	discussion	discussion	NOUN
ajlm-823	1	6	acknowledgements	acknowledgement	NOUN
ajlm-823	1	7	references	reference	NOUN
ajlm-823	1	8	about	about	ADP
ajlm-823	1	9	the	the	DET
ajlm-823	1	10	author(s	author(s	NOUN
ajlm-823	1	11	)	)	PUNCT
ajlm-823	1	12	erius	erius	PROPN
ajlm-823	1	13	tebuka	tebuka	PROPN
ajlm-823	1	14	department	department	PROPN
ajlm-823	1	15	of	of	ADP
ajlm-823	1	16	pathology	pathology	PROPN
ajlm-823	1	17	,	,	PUNCT
ajlm-823	1	18	weill	weill	PROPN
ajlm-823	1	19	bugando	bugando	ADJ
ajlm-823	1	20	school	school	NOUN
ajlm-823	1	21	of	of	ADP
ajlm-823	1	22	medicine	medicine	NOUN
ajlm-823	1	23	,	,	PUNCT
ajlm-823	1	24	mwanza	mwanza	PROPN
ajlm-823	1	25	,	,	PUNCT
ajlm-823	1	26	united	united	PROPN
ajlm-823	1	27	republic	republic	PROPN
ajlm-823	1	28	of	of	ADP
ajlm-823	1	29	tanzania	tanzania	PROPN
ajlm-823	1	30	bugando	bugando	PROPN
ajlm-823	1	31	medical	medical	ADJ
ajlm-823	1	32	centre	centre	NOUN
ajlm-823	1	33	,	,	PUNCT
ajlm-823	1	34	mwanza	mwanza	PROPN
ajlm-823	1	35	,	,	PUNCT
ajlm-823	1	36	united	united	PROPN
ajlm-823	1	37	republic	republic	PROPN
ajlm-823	1	38	of	of	ADP
ajlm-823	1	39	tanzania	tanzania	PROPN
ajlm-823	1	40	mwesige	mwesige	PROPN
ajlm-823	1	41	charles	charles	PROPN
ajlm-823	1	42	central	central	PROPN
ajlm-823	1	43	pathology	pathology	PROPN
ajlm-823	1	44	laboratory	laboratory	NOUN
ajlm-823	1	45	,	,	PUNCT
ajlm-823	1	46	bugando	bugando	ADJ
ajlm-823	1	47	medical	medical	ADJ
ajlm-823	1	48	centre	centre	NOUN
ajlm-823	1	49	,	,	PUNCT
ajlm-823	1	50	department	department	NOUN
ajlm-823	1	51	of	of	ADP
ajlm-823	1	52	hematology	hematology	PROPN
ajlm-823	1	53	,	,	PUNCT
ajlm-823	1	54	mwanza	mwanza	PROPN
ajlm-823	1	55	,	,	PUNCT
ajlm-823	1	56	united	united	PROPN
ajlm-823	1	57	republic	republic	PROPN
ajlm-823	1	58	of	of	ADP
ajlm-823	1	59	tanzania	tanzania	PROPN
ajlm-823	1	60	jeffer	jeffer	PROPN
ajlm-823	1	61	o.	o.	PROPN
ajlm-823	1	62	bhuko	bhuko	PROPN
ajlm-823	1	63	department	department	PROPN
ajlm-823	1	64	of	of	ADP
ajlm-823	1	65	pathology	pathology	PROPN
ajlm-823	1	66	,	,	PUNCT
ajlm-823	1	67	weill	weill	PROPN
ajlm-823	1	68	bugando	bugando	ADJ
ajlm-823	1	69	school	school	NOUN
ajlm-823	1	70	of	of	ADP
ajlm-823	1	71	medicine	medicine	NOUN
ajlm-823	1	72	,	,	PUNCT
ajlm-823	1	73	mwanza	mwanza	PROPN
ajlm-823	1	74	,	,	PUNCT
ajlm-823	1	75	united	united	PROPN
ajlm-823	1	76	republic	republic	PROPN
ajlm-823	1	77	of	of	ADP
ajlm-823	1	78	tanzania	tanzania	PROPN
ajlm-823	1	79	bugando	bugando	PROPN
ajlm-823	1	80	medical	medical	ADJ
ajlm-823	1	81	centre	centre	NOUN
ajlm-823	1	82	,	,	PUNCT
ajlm-823	1	83	mwanza	mwanza	PROPN
ajlm-823	1	84	,	,	PUNCT
ajlm-823	1	85	united	united	PROPN
ajlm-823	1	86	republic	republic	PROPN
ajlm-823	1	87	of	of	ADP
ajlm-823	1	88	tanzania	tanzania	PROPN
ajlm-823	1	89	mwanza	mwanza	PROPN
ajlm-823	1	90	region	region	PROPN
ajlm-823	1	91	health	health	NOUN
ajlm-823	1	92	center	center	NOUN
ajlm-823	1	93	,	,	PUNCT
ajlm-823	1	94	mwanza	mwanza	PROPN
ajlm-823	1	95	,	,	PUNCT
ajlm-823	1	96	united	united	PROPN
ajlm-823	1	97	republic	republic	PROPN
ajlm-823	1	98	of	of	ADP
ajlm-823	1	99	tanzania	tanzania	PROPN
ajlm-823	1	100	citation	citation	PROPN
ajlm-823	1	101	tebuka	tebuka	PROPN
ajlm-823	1	102	e	e	PROPN
ajlm-823	1	103	,	,	PUNCT
ajlm-823	1	104	charles	charles	PROPN
ajlm-823	1	105	m	m	PROPN
ajlm-823	1	106	,	,	PUNCT
ajlm-823	1	107	bhuko	bhuko	PROPN
ajlm-823	1	108	jo	jo	PROPN
ajlm-823	1	109	.	.	PUNCT
ajlm-823	2	1	prevalence	prevalence	NOUN
ajlm-823	2	2	and	and	CCONJ
ajlm-823	2	3	risk	risk	NOUN
ajlm-823	2	4	factors	factor	NOUN
ajlm-823	2	5	for	for	ADP
ajlm-823	2	6	red	red	ADJ
ajlm-823	2	7	blood	blood	NOUN
ajlm-823	2	8	cell	cell	NOUN
ajlm-823	2	9	alloimmunisation	alloimmunisation	NOUN
ajlm-823	2	10	among	among	ADP
ajlm-823	2	11	sickle	sickle	NOUN
ajlm-823	2	12	cell	cell	NOUN
ajlm-823	2	13	patients	patient	NOUN
ajlm-823	2	14	in	in	ADP
ajlm-823	2	15	mwanza	mwanza	PROPN
ajlm-823	2	16	city	city	PROPN
ajlm-823	2	17	,	,	PUNCT
ajlm-823	2	18	tanzania	tanzania	PROPN
ajlm-823	2	19	.	.	PUNCT
ajlm-823	3	1	afr	afr	PROPN
ajlm-823	3	2	j	j	PROPN
ajlm-823	3	3	lab	lab	PROPN
ajlm-823	3	4	med	me	VERB
ajlm-823	3	5	.	.	PUNCT
ajlm-823	3	6	2020;9(1	2020;9(1	NUM
ajlm-823	3	7	)	)	PUNCT
ajlm-823	3	8	,	,	PUNCT
ajlm-823	3	9	a823	a823	PROPN
ajlm-823	3	10	.	.	PROPN
ajlm-823	3	11	https://doi.org/10.4102/ajlm.v9i1.823	https://doi.org/10.4102/ajlm.v9i1.823	ADJ
ajlm-823	3	12	original	original	ADJ
ajlm-823	3	13	research	research	NOUN
ajlm-823	3	14	prevalence	prevalence	NOUN
ajlm-823	3	15	and	and	CCONJ
ajlm-823	3	16	risk	risk	NOUN
ajlm-823	3	17	factors	factor	NOUN
ajlm-823	3	18	for	for	ADP
ajlm-823	3	19	red	red	ADJ
ajlm-823	3	20	blood	blood	NOUN
ajlm-823	3	21	cell	cell	NOUN
ajlm-823	3	22	alloimmunisation	alloimmunisation	NOUN
ajlm-823	3	23	among	among	ADP
ajlm-823	3	24	sickle	sickle	NOUN
ajlm-823	3	25	cell	cell	NOUN
ajlm-823	3	26	patients	patient	NOUN
ajlm-823	3	27	in	in	ADP
ajlm-823	3	28	mwanza	mwanza	PROPN
ajlm-823	3	29	city	city	PROPN
ajlm-823	3	30	,	,	PUNCT
ajlm-823	3	31	tanzania	tanzania	PROPN
ajlm-823	3	32	erius	erius	PROPN
ajlm-823	3	33	tebuka	tebuka	PROPN
ajlm-823	3	34	,	,	PUNCT
ajlm-823	3	35	mwesige	mwesige	PROPN
ajlm-823	3	36	charles	charles	PROPN
ajlm-823	3	37	,	,	PUNCT
ajlm-823	3	38	jeffer	jeffer	NOUN
ajlm-823	3	39	o.	o.	PROPN
ajlm-823	3	40	bhuko	bhuko	PROPN
ajlm-823	3	41	received	receive	VERB
ajlm-823	3	42	:	:	PUNCT
ajlm-823	3	43	01	01	NUM
ajlm-823	3	44	may	may	PROPN
ajlm-823	3	45	2018	2018	NUM
ajlm-823	3	46	;	;	PUNCT
ajlm-823	3	47	accepted	accept	VERB
ajlm-823	3	48	:	:	PUNCT
ajlm-823	3	49	05	05	NUM
ajlm-823	3	50	mar	mar	PROPN
ajlm-823	3	51	.	.	PROPN
ajlm-823	3	52	2019	2019	NUM
ajlm-823	3	53	;	;	PUNCT
ajlm-823	3	54	published	publish	VERB
ajlm-823	3	55	:	:	PUNCT
ajlm-823	3	56	10	10	NUM
ajlm-823	3	57	sept	sept	PROPN
ajlm-823	3	58	.	.	PROPN
ajlm-823	3	59	2020	2020	NUM
ajlm-823	3	60	copyright	copyright	NOUN
ajlm-823	3	61	:	:	PUNCT
ajlm-823	3	62	©	©	PROPN
ajlm-823	3	63	2020	2020	NUM
ajlm-823	3	64	.	.	PUNCT
ajlm-823	4	1	the	the	DET
ajlm-823	4	2	author(s	author(s	PROPN
ajlm-823	4	3	)	)	PUNCT
ajlm-823	4	4	.	.	PUNCT
ajlm-823	5	1	licensee	licensee	NOUN
ajlm-823	5	2	:	:	PUNCT
ajlm-823	5	3	aosis	aosis	NOUN
ajlm-823	5	4	.	.	PUNCT
ajlm-823	6	1	this	this	PRON
ajlm-823	6	2	is	be	AUX
ajlm-823	6	3	an	an	DET
ajlm-823	6	4	open	open	ADJ
ajlm-823	6	5	access	access	NOUN
ajlm-823	6	6	article	article	NOUN
ajlm-823	6	7	distributed	distribute	VERB
ajlm-823	6	8	under	under	ADP
ajlm-823	6	9	the	the	DET
ajlm-823	6	10	terms	term	NOUN
ajlm-823	6	11	of	of	ADP
ajlm-823	6	12	the	the	DET
ajlm-823	6	13	creative	creative	ADJ
ajlm-823	6	14	commons	common	NOUN
ajlm-823	6	15	attribution	attribution	NOUN
ajlm-823	6	16	license	license	NOUN
ajlm-823	6	17	,	,	PUNCT
ajlm-823	6	18	which	which	PRON
ajlm-823	6	19	permits	permit	VERB
ajlm-823	6	20	unrestricted	unrestricted	ADJ
ajlm-823	6	21	use	use	NOUN
ajlm-823	6	22	,	,	PUNCT
ajlm-823	6	23	distribution	distribution	NOUN
ajlm-823	6	24	,	,	PUNCT
ajlm-823	6	25	and	and	CCONJ
ajlm-823	6	26	reproduction	reproduction	NOUN
ajlm-823	6	27	in	in	ADP
ajlm-823	6	28	any	any	DET
ajlm-823	6	29	medium	medium	NOUN
ajlm-823	6	30	,	,	PUNCT
ajlm-823	6	31	provided	provide	VERB
ajlm-823	6	32	the	the	DET
ajlm-823	6	33	original	original	ADJ
ajlm-823	6	34	work	work	NOUN
ajlm-823	6	35	is	be	AUX
ajlm-823	6	36	properly	properly	ADV
ajlm-823	6	37	cited	cite	VERB
ajlm-823	6	38	.	.	PUNCT
ajlm-823	7	1	abstract	abstract	ADJ
ajlm-823	7	2	background	background	NOUN
ajlm-823	7	3	:	:	PUNCT
ajlm-823	7	4	erythrocyte	erythrocyte	ADJ
ajlm-823	7	5	alloimmunisation	alloimmunisation	NOUN
ajlm-823	7	6	can	can	AUX
ajlm-823	7	7	lead	lead	VERB
ajlm-823	7	8	to	to	ADP
ajlm-823	7	9	complications	complication	NOUN
ajlm-823	7	10	such	such	ADJ
ajlm-823	7	11	as	as	ADP
ajlm-823	7	12	delayed	delay	VERB
ajlm-823	7	13	haemolytic	haemolytic	ADJ
ajlm-823	7	14	transfusion	transfusion	NOUN
ajlm-823	7	15	reaction	reaction	NOUN
ajlm-823	7	16	.	.	PUNCT
ajlm-823	8	1	objective	objective	NOUN
ajlm-823	8	2	:	:	PUNCT
ajlm-823	8	3	this	this	DET
ajlm-823	8	4	study	study	NOUN
ajlm-823	8	5	investigated	investigate	VERB
ajlm-823	8	6	the	the	DET
ajlm-823	8	7	prevalence	prevalence	NOUN
ajlm-823	8	8	of	of	ADP
ajlm-823	8	9	and	and	CCONJ
ajlm-823	8	10	risk	risk	NOUN
ajlm-823	8	11	factors	factor	NOUN
ajlm-823	8	12	for	for	ADP
ajlm-823	8	13	red	red	ADJ
ajlm-823	8	14	blood	blood	NOUN
ajlm-823	8	15	cell	cell	NOUN
ajlm-823	8	16	alloimmunisation	alloimmunisation	NOUN
ajlm-823	8	17	among	among	ADP
ajlm-823	8	18	multiply	multiply	NOUN
ajlm-823	8	19	transfused	transfused	ADJ
ajlm-823	8	20	sickle	sickle	NOUN
ajlm-823	8	21	cell	cell	NOUN
ajlm-823	8	22	disease	disease	NOUN
ajlm-823	8	23	(	(	PUNCT
ajlm-823	8	24	scd	scd	NOUN
ajlm-823	8	25	)	)	PUNCT
ajlm-823	8	26	patients	patient	NOUN
ajlm-823	8	27	in	in	ADP
ajlm-823	8	28	mwanza	mwanza	PROPN
ajlm-823	8	29	city	city	PROPN
ajlm-823	8	30	,	,	PUNCT
ajlm-823	8	31	tanzania	tanzania	PROPN
ajlm-823	8	32	.	.	PUNCT
ajlm-823	9	1	methods	method	NOUN
ajlm-823	9	2	:	:	PUNCT
ajlm-823	9	3	from	from	ADP
ajlm-823	9	4	may	may	PROPN
ajlm-823	9	5	2017	2017	NUM
ajlm-823	9	6	to	to	ADP
ajlm-823	9	7	july	july	PROPN
ajlm-823	9	8	2017	2017	NUM
ajlm-823	9	9	,	,	PUNCT
ajlm-823	9	10	this	this	DET
ajlm-823	9	11	descriptive	descriptive	ADJ
ajlm-823	9	12	,	,	PUNCT
ajlm-823	9	13	cross	cross	ADJ
ajlm-823	9	14	-	-	ADJ
ajlm-823	9	15	sectional	sectional	ADJ
ajlm-823	9	16	,	,	PUNCT
ajlm-823	9	17	hospital	hospital	NOUN
ajlm-823	9	18	-	-	PUNCT
ajlm-823	9	19	based	base	VERB
ajlm-823	9	20	study	study	NOUN
ajlm-823	9	21	enrolled	enrol	VERB
ajlm-823	9	22	200	200	NUM
ajlm-823	9	23	participants	participant	NOUN
ajlm-823	9	24	with	with	ADP
ajlm-823	9	25	scd	scd	PROPN
ajlm-823	9	26	who	who	PRON
ajlm-823	9	27	had	have	AUX
ajlm-823	9	28	received	receive	VERB
ajlm-823	9	29	at	at	ADP
ajlm-823	9	30	least	least	ADV
ajlm-823	9	31	two	two	NUM
ajlm-823	9	32	units	unit	NOUN
ajlm-823	9	33	of	of	ADP
ajlm-823	9	34	blood	blood	NOUN
ajlm-823	9	35	in	in	ADP
ajlm-823	9	36	the	the	DET
ajlm-823	9	37	previous	previous	ADJ
ajlm-823	9	38	year	year	NOUN
ajlm-823	9	39	.	.	PUNCT
ajlm-823	10	1	blood	blood	NOUN
ajlm-823	10	2	count	count	NOUN
ajlm-823	10	3	was	be	AUX
ajlm-823	10	4	performed	perform	VERB
ajlm-823	10	5	using	use	VERB
ajlm-823	10	6	a	a	DET
ajlm-823	10	7	sysmex	sysmex	NOUN
ajlm-823	10	8	haematology	haematology	NOUN
ajlm-823	10	9	analyser	analyser	NOUN
ajlm-823	10	10	.	.	PUNCT
ajlm-823	11	1	antibody	antibody	NOUN
ajlm-823	11	2	screening	screen	VERB
ajlm-823	11	3	was	be	AUX
ajlm-823	11	4	done	do	VERB
ajlm-823	11	5	by	by	ADP
ajlm-823	11	6	the	the	DET
ajlm-823	11	7	tube	tube	NOUN
ajlm-823	11	8	method	method	NOUN
ajlm-823	11	9	using	use	VERB
ajlm-823	11	10	a	a	DET
ajlm-823	11	11	panel	panel	NOUN
ajlm-823	11	12	of	of	ADP
ajlm-823	11	13	three	three	NUM
ajlm-823	11	14	screening	screen	VERB
ajlm-823	11	15	cells	cell	NOUN
ajlm-823	11	16	with	with	ADP
ajlm-823	11	17	known	know	VERB
ajlm-823	11	18	antigenicity	antigenicity	NOUN
ajlm-823	11	19	.	.	PUNCT
ajlm-823	12	1	results	result	NOUN
ajlm-823	12	2	:	:	PUNCT
ajlm-823	12	3	of	of	ADP
ajlm-823	12	4	the	the	DET
ajlm-823	12	5	200	200	NUM
ajlm-823	12	6	patients	patient	NOUN
ajlm-823	12	7	enrolled	enrol	VERB
ajlm-823	12	8	,	,	PUNCT
ajlm-823	12	9	108	108	NUM
ajlm-823	12	10	(	(	PUNCT
ajlm-823	12	11	54	54	NUM
ajlm-823	12	12	%	%	NOUN
ajlm-823	12	13	)	)	PUNCT
ajlm-823	12	14	were	be	AUX
ajlm-823	12	15	female	female	ADJ
ajlm-823	12	16	.	.	PUNCT
ajlm-823	13	1	the	the	DET
ajlm-823	13	2	median	median	ADJ
ajlm-823	13	3	age	age	NOUN
ajlm-823	13	4	was	be	AUX
ajlm-823	13	5	4.5	4.5	NUM
ajlm-823	13	6	years	year	NOUN
ajlm-823	13	7	(	(	PUNCT
ajlm-823	13	8	interquartile	interquartile	NOUN
ajlm-823	13	9	range	range	NOUN
ajlm-823	13	10	[	[	X
ajlm-823	13	11	iqr	iqr	X
ajlm-823	13	12	]	]	X
ajlm-823	13	13	=	=	SYM
ajlm-823	13	14	6	6	NUM
ajlm-823	13	15	)	)	PUNCT
ajlm-823	13	16	,	,	PUNCT
ajlm-823	13	17	the	the	DET
ajlm-823	13	18	median	median	ADJ
ajlm-823	13	19	number	number	NOUN
ajlm-823	13	20	of	of	ADP
ajlm-823	13	21	transfusions	transfusion	NOUN
ajlm-823	13	22	was	be	AUX
ajlm-823	13	23	3	3	NUM
ajlm-823	13	24	(	(	PUNCT
ajlm-823	13	25	iqr	iqr	NOUN
ajlm-823	13	26	=	=	NOUN
ajlm-823	13	27	1	1	NUM
ajlm-823	13	28	)	)	PUNCT
ajlm-823	13	29	,	,	PUNCT
ajlm-823	13	30	and	and	CCONJ
ajlm-823	13	31	the	the	DET
ajlm-823	13	32	median	median	ADJ
ajlm-823	13	33	pre	pre	ADJ
ajlm-823	13	34	-	-	ADJ
ajlm-823	13	35	transfusion	transfusion	ADJ
ajlm-823	13	36	haemoglobin	haemoglobin	NOUN
ajlm-823	13	37	level	level	NOUN
ajlm-823	13	38	was	be	AUX
ajlm-823	13	39	6.6	6.6	NUM
ajlm-823	13	40	g	g	NOUN
ajlm-823	13	41	/	/	SYM
ajlm-823	13	42	dl	dl	PROPN
ajlm-823	13	43	(	(	PUNCT
ajlm-823	13	44	iqr	iqr	PROPN
ajlm-823	13	45	=	=	NOUN
ajlm-823	13	46	2.7	2.7	NUM
ajlm-823	13	47	)	)	PUNCT
ajlm-823	13	48	.	.	PUNCT
ajlm-823	14	1	prevalence	prevalence	NOUN
ajlm-823	14	2	of	of	ADP
ajlm-823	14	3	alloimmunisation	alloimmunisation	NOUN
ajlm-823	14	4	was	be	AUX
ajlm-823	14	5	8.5	8.5	NUM
ajlm-823	14	6	%	%	NOUN
ajlm-823	14	7	(	(	PUNCT
ajlm-823	14	8	17/200	17/200	NUM
ajlm-823	14	9	)	)	PUNCT
ajlm-823	14	10	with	with	ADP
ajlm-823	14	11	immunoglobulin	immunoglobulin	NOUN
ajlm-823	14	12	g	g	PROPN
ajlm-823	14	13	,	,	PUNCT
ajlm-823	14	14	and	and	CCONJ
ajlm-823	14	15	one	one	NUM
ajlm-823	14	16	patient	patient	NOUN
ajlm-823	14	17	developed	develop	VERB
ajlm-823	14	18	cold	cold	ADJ
ajlm-823	14	19	immunoglobulin	immunoglobulin	NOUN
ajlm-823	14	20	m	m	PROPN
ajlm-823	14	21	antibodies	antibodie	VERB
ajlm-823	14	22	.	.	PUNCT
ajlm-823	15	1	blood	blood	NOUN
ajlm-823	15	2	groups	group	NOUN
ajlm-823	15	3	reported	report	VERB
ajlm-823	15	4	were	be	AUX
ajlm-823	15	5	rhesus	rhesus	NOUN
ajlm-823	15	6	c	c	PROPN
ajlm-823	15	7	and	and	CCONJ
ajlm-823	15	8	e	e	PROPN
ajlm-823	15	9	,	,	PUNCT
ajlm-823	15	10	kell	kell	PROPN
ajlm-823	15	11	,	,	PUNCT
ajlm-823	15	12	kidd	kidd	PROPN
ajlm-823	15	13	and	and	CCONJ
ajlm-823	15	14	duffy	duffy	PROPN
ajlm-823	15	15	.	.	PUNCT
ajlm-823	16	1	there	there	PRON
ajlm-823	16	2	was	be	VERB
ajlm-823	16	3	no	no	DET
ajlm-823	16	4	statistically	statistically	ADV
ajlm-823	16	5	significant	significant	ADJ
ajlm-823	16	6	association	association	NOUN
ajlm-823	16	7	between	between	ADP
ajlm-823	16	8	the	the	DET
ajlm-823	16	9	number	number	NOUN
ajlm-823	16	10	of	of	ADP
ajlm-823	16	11	transfusions	transfusion	NOUN
ajlm-823	16	12	and	and	CCONJ
ajlm-823	16	13	the	the	DET
ajlm-823	16	14	risk	risk	NOUN
ajlm-823	16	15	of	of	ADP
ajlm-823	16	16	alloimmunisation	alloimmunisation	NOUN
ajlm-823	16	17	.	.	PUNCT
ajlm-823	17	1	conclusion	conclusion	NOUN
ajlm-823	17	2	:	:	PUNCT
ajlm-823	17	3	the	the	DET
ajlm-823	17	4	rate	rate	NOUN
ajlm-823	17	5	of	of	ADP
ajlm-823	17	6	alloimmunisation	alloimmunisation	NOUN
ajlm-823	17	7	in	in	ADP
ajlm-823	17	8	multiply	multiply	NOUN
ajlm-823	17	9	transfused	transfused	ADJ
ajlm-823	17	10	scd	scd	NOUN
ajlm-823	17	11	patients	patient	NOUN
ajlm-823	17	12	was	be	AUX
ajlm-823	17	13	8.5	8.5	NUM
ajlm-823	17	14	%	%	NOUN
ajlm-823	17	15	and	and	CCONJ
ajlm-823	17	16	higher	high	ADJ
ajlm-823	17	17	than	than	ADP
ajlm-823	17	18	other	other	ADJ
ajlm-823	17	19	studies	study	NOUN
ajlm-823	17	20	in	in	ADP
ajlm-823	17	21	east	east	PROPN
ajlm-823	17	22	africa	africa	PROPN
ajlm-823	17	23	.	.	PUNCT
ajlm-823	18	1	thus	thus	ADV
ajlm-823	18	2	,	,	PUNCT
ajlm-823	18	3	there	there	PRON
ajlm-823	18	4	is	be	VERB
ajlm-823	18	5	a	a	DET
ajlm-823	18	6	need	need	NOUN
ajlm-823	18	7	for	for	ADP
ajlm-823	18	8	extensive	extensive	ADJ
ajlm-823	18	9	red	red	ADJ
ajlm-823	18	10	blood	blood	NOUN
ajlm-823	18	11	cell	cell	NOUN
ajlm-823	18	12	screening	screening	NOUN
ajlm-823	18	13	and	and	CCONJ
ajlm-823	18	14	matching	match	VERB
ajlm-823	18	15	to	to	PART
ajlm-823	18	16	minimize	minimize	VERB
ajlm-823	18	17	alloimmunisation	alloimmunisation	NOUN
ajlm-823	18	18	and	and	CCONJ
ajlm-823	18	19	risk	risk	NOUN
ajlm-823	18	20	of	of	ADP
ajlm-823	18	21	delayed	delay	VERB
ajlm-823	18	22	haemolytic	haemolytic	ADJ
ajlm-823	18	23	transfusion	transfusion	NOUN
ajlm-823	18	24	reaction	reaction	NOUN
ajlm-823	18	25	,	,	PUNCT
ajlm-823	18	26	particularly	particularly	ADV
ajlm-823	18	27	in	in	ADP
ajlm-823	18	28	scd	scd	NOUN
ajlm-823	18	29	and	and	CCONJ
ajlm-823	18	30	chronically	chronically	ADV
ajlm-823	18	31	transfused	transfused	ADJ
ajlm-823	18	32	patients	patient	NOUN
ajlm-823	18	33	.	.	PUNCT
ajlm-823	19	1	keywords	keyword	NOUN
ajlm-823	19	2	:	:	PUNCT
ajlm-823	19	3	sickle	sickle	NOUN
ajlm-823	19	4	cell	cell	NOUN
ajlm-823	19	5	disease	disease	NOUN
ajlm-823	19	6	;	;	PUNCT
ajlm-823	19	7	alloimmunisation	alloimmunisation	NOUN
ajlm-823	19	8	;	;	PUNCT
ajlm-823	19	9	alloantibody	alloantibody	ADJ
ajlm-823	19	10	;	;	PUNCT
ajlm-823	19	11	screening	screen	VERB
ajlm-823	19	12	cells	cell	NOUN
ajlm-823	19	13	;	;	PUNCT
ajlm-823	19	14	bugando	bugando	ADJ
ajlm-823	19	15	medical	medical	ADJ
ajlm-823	19	16	centre	centre	NOUN
ajlm-823	19	17	;	;	PUNCT
ajlm-823	19	18	catholic	catholic	PROPN
ajlm-823	19	19	university	university	PROPN
ajlm-823	19	20	of	of	ADP
ajlm-823	19	21	health	health	PROPN
ajlm-823	19	22	and	and	CCONJ
ajlm-823	19	23	allied	ally	VERB
ajlm-823	19	24	sciences	science	NOUN
ajlm-823	19	25	;	;	PUNCT
ajlm-823	19	26	red	red	ADJ
ajlm-823	19	27	blood	blood	NOUN
ajlm-823	19	28	cells	cell	NOUN
ajlm-823	19	29	.	.	PUNCT
ajlm-823	20	1	introduction	introduction	NOUN
ajlm-823	20	2	sickle	sickle	NOUN
ajlm-823	20	3	cell	cell	NOUN
ajlm-823	20	4	disease	disease	NOUN
ajlm-823	20	5	(	(	PUNCT
ajlm-823	20	6	scd	scd	NOUN
ajlm-823	20	7	)	)	PUNCT
ajlm-823	20	8	is	be	AUX
ajlm-823	20	9	an	an	DET
ajlm-823	20	10	inherited	inherit	VERB
ajlm-823	20	11	haemoglobin	haemoglobin	NOUN
ajlm-823	20	12	disorder	disorder	NOUN
ajlm-823	20	13	;	;	PUNCT
ajlm-823	20	14	it	it	PRON
ajlm-823	20	15	is	be	AUX
ajlm-823	20	16	a	a	DET
ajlm-823	20	17	genetic	genetic	ADJ
ajlm-823	20	18	disease	disease	NOUN
ajlm-823	20	19	with	with	ADP
ajlm-823	20	20	high	high	ADJ
ajlm-823	20	21	prevalence	prevalence	NOUN
ajlm-823	20	22	in	in	ADP
ajlm-823	20	23	the	the	DET
ajlm-823	20	24	equatorial	equatorial	ADJ
ajlm-823	20	25	regions	region	NOUN
ajlm-823	20	26	of	of	ADP
ajlm-823	20	27	africa	africa	PROPN
ajlm-823	20	28	,	,	PUNCT
ajlm-823	20	29	arabia	arabia	PROPN
ajlm-823	20	30	,	,	PUNCT
ajlm-823	20	31	europe	europe	PROPN
ajlm-823	20	32	,	,	PUNCT
ajlm-823	20	33	and	and	CCONJ
ajlm-823	20	34	india	india	PROPN
ajlm-823	20	35	.	.	PUNCT
ajlm-823	21	1	globally	globally	ADV
ajlm-823	21	2	,	,	PUNCT
ajlm-823	21	3	approximately	approximately	ADV
ajlm-823	21	4	300	300	NUM
ajlm-823	21	5	000	000	NUM
ajlm-823	21	6	people	people	NOUN
ajlm-823	21	7	are	be	AUX
ajlm-823	21	8	born	bear	VERB
ajlm-823	21	9	with	with	ADP
ajlm-823	21	10	scd	scd	PROPN
ajlm-823	21	11	annually.1	annually.1	PROPN
ajlm-823	21	12	blood	blood	NOUN
ajlm-823	21	13	transfusions	transfusion	NOUN
ajlm-823	21	14	are	be	AUX
ajlm-823	21	15	necessary	necessary	ADJ
ajlm-823	21	16	for	for	SCONJ
ajlm-823	21	17	the	the	DET
ajlm-823	21	18	care	care	NOUN
ajlm-823	21	19	and	and	CCONJ
ajlm-823	21	20	treatment	treatment	NOUN
ajlm-823	21	21	of	of	ADP
ajlm-823	21	22	patients	patient	NOUN
ajlm-823	21	23	with	with	ADP
ajlm-823	21	24	scd.2,3	scd.2,3	PROPN
ajlm-823	21	25	in	in	ADP
ajlm-823	21	26	africa	africa	PROPN
ajlm-823	21	27	,	,	PUNCT
ajlm-823	21	28	including	include	VERB
ajlm-823	21	29	tanzania	tanzania	PROPN
ajlm-823	21	30	,	,	PUNCT
ajlm-823	21	31	and	and	CCONJ
ajlm-823	21	32	the	the	DET
ajlm-823	21	33	middle	middle	PROPN
ajlm-823	21	34	east	east	PROPN
ajlm-823	21	35	,	,	PUNCT
ajlm-823	21	36	the	the	DET
ajlm-823	21	37	abo	abo	NOUN
ajlm-823	21	38	and	and	CCONJ
ajlm-823	21	39	rhesus	rhesus	NOUN
ajlm-823	21	40	d	d	NOUN
ajlm-823	21	41	blood	blood	NOUN
ajlm-823	21	42	grouping	group	VERB
ajlm-823	21	43	system	system	NOUN
ajlm-823	21	44	are	be	AUX
ajlm-823	21	45	as	as	ADP
ajlm-823	21	46	the	the	DET
ajlm-823	21	47	test	test	NOUN
ajlm-823	21	48	parameters	parameter	NOUN
ajlm-823	21	49	for	for	ADP
ajlm-823	21	50	blood	blood	NOUN
ajlm-823	21	51	transfusion	transfusion	NOUN
ajlm-823	21	52	,	,	PUNCT
ajlm-823	21	53	neglecting	neglect	VERB
ajlm-823	21	54	other	other	ADJ
ajlm-823	21	55	red	red	ADJ
ajlm-823	21	56	blood	blood	NOUN
ajlm-823	21	57	cell	cell	NOUN
ajlm-823	21	58	surface	surface	NOUN
ajlm-823	21	59	antigens	antigen	NOUN
ajlm-823	21	60	,	,	PUNCT
ajlm-823	21	61	which	which	PRON
ajlm-823	21	62	are	be	AUX
ajlm-823	21	63	considered	consider	VERB
ajlm-823	21	64	minority	minority	NOUN
ajlm-823	21	65	blood	blood	NOUN
ajlm-823	21	66	groups	group	NOUN
ajlm-823	21	67	.	.	PUNCT
ajlm-823	22	1	however	however	ADV
ajlm-823	22	2	,	,	PUNCT
ajlm-823	22	3	this	this	PRON
ajlm-823	22	4	can	can	AUX
ajlm-823	22	5	cause	cause	VERB
ajlm-823	22	6	serious	serious	ADJ
ajlm-823	22	7	complications	complication	NOUN
ajlm-823	22	8	,	,	PUNCT
ajlm-823	22	9	including	include	VERB
ajlm-823	22	10	alloimmunisation	alloimmunisation	NOUN
ajlm-823	22	11	in	in	ADP
ajlm-823	22	12	scd	scd	PROPN
ajlm-823	22	13	patients	patient	NOUN
ajlm-823	22	14	,	,	PUNCT
ajlm-823	22	15	once	once	ADV
ajlm-823	22	16	a	a	DET
ajlm-823	22	17	transfusion	transfusion	NOUN
ajlm-823	22	18	is	be	AUX
ajlm-823	22	19	done	do	VERB
ajlm-823	22	20	,	,	PUNCT
ajlm-823	22	21	without	without	ADP
ajlm-823	22	22	a	a	DET
ajlm-823	22	23	thorough	thorough	ADJ
ajlm-823	22	24	and	and	CCONJ
ajlm-823	22	25	complete	complete	ADJ
ajlm-823	22	26	screening	screening	NOUN
ajlm-823	22	27	of	of	ADP
ajlm-823	22	28	the	the	DET
ajlm-823	22	29	antigenicity	antigenicity	NOUN
ajlm-823	22	30	of	of	ADP
ajlm-823	22	31	both	both	CCONJ
ajlm-823	22	32	the	the	DET
ajlm-823	22	33	donor	donor	NOUN
ajlm-823	22	34	and	and	CCONJ
ajlm-823	22	35	the	the	DET
ajlm-823	22	36	recipient.4	recipient.4	PROPN
ajlm-823	22	37	alloimmunisation	alloimmunisation	NOUN
ajlm-823	22	38	is	be	AUX
ajlm-823	22	39	the	the	DET
ajlm-823	22	40	body	body	NOUN
ajlm-823	22	41	’s	’s	PART
ajlm-823	22	42	response	response	NOUN
ajlm-823	22	43	to	to	ADP
ajlm-823	22	44	foreign	foreign	ADJ
ajlm-823	22	45	antigens	antigen	NOUN
ajlm-823	22	46	after	after	ADP
ajlm-823	22	47	being	be	AUX
ajlm-823	22	48	subjected	subject	VERB
ajlm-823	22	49	to	to	ADP
ajlm-823	22	50	cells	cell	NOUN
ajlm-823	22	51	or	or	CCONJ
ajlm-823	22	52	tissues	tissue	NOUN
ajlm-823	22	53	with	with	ADP
ajlm-823	22	54	different	different	ADJ
ajlm-823	22	55	antigenicity.5	antigenicity.5	PROPN
ajlm-823	22	56	complications	complication	NOUN
ajlm-823	22	57	of	of	ADP
ajlm-823	22	58	alloimmunisation	alloimmunisation	NOUN
ajlm-823	22	59	include	include	VERB
ajlm-823	22	60	life	life	NOUN
ajlm-823	22	61	-	-	PUNCT
ajlm-823	22	62	threatening	threaten	VERB
ajlm-823	22	63	conditions	condition	NOUN
ajlm-823	22	64	such	such	ADJ
ajlm-823	22	65	as	as	ADP
ajlm-823	22	66	delayed	delay	VERB
ajlm-823	22	67	hemolytic	hemolytic	ADJ
ajlm-823	22	68	transfusion	transfusion	NOUN
ajlm-823	22	69	reactions	reaction	NOUN
ajlm-823	22	70	,	,	PUNCT
ajlm-823	22	71	immediate	immediate	ADJ
ajlm-823	22	72	agglutination	agglutination	NOUN
ajlm-823	22	73	,	,	PUNCT
ajlm-823	22	74	hyper	hyper	ADJ
ajlm-823	22	75	hemolysis2	hemolysis2	NOUN
ajlm-823	22	76	and	and	CCONJ
ajlm-823	22	77	autoimmune	autoimmune	ADJ
ajlm-823	22	78	responses	response	NOUN
ajlm-823	22	79	in	in	ADP
ajlm-823	22	80	individuals	individual	NOUN
ajlm-823	22	81	having	have	VERB
ajlm-823	22	82	blood	blood	NOUN
ajlm-823	22	83	transfusions	transfusion	NOUN
ajlm-823	22	84	,	,	PUNCT
ajlm-823	22	85	especially	especially	ADV
ajlm-823	22	86	scd	scd	NOUN
ajlm-823	22	87	patients	patient	NOUN
ajlm-823	22	88	.	.	PUNCT
ajlm-823	23	1	studies	study	NOUN
ajlm-823	23	2	have	have	AUX
ajlm-823	23	3	shown	show	VERB
ajlm-823	23	4	that	that	SCONJ
ajlm-823	23	5	antigenicity	antigenicity	NOUN
ajlm-823	23	6	matching	matching	NOUN
ajlm-823	23	7	,	,	PUNCT
ajlm-823	23	8	for	for	ADP
ajlm-823	23	9	scd	scd	NOUN
ajlm-823	23	10	and	and	CCONJ
ajlm-823	23	11	chronically	chronically	ADV
ajlm-823	23	12	transfused	transfused	ADJ
ajlm-823	23	13	patients	patient	NOUN
ajlm-823	23	14	,	,	PUNCT
ajlm-823	23	15	is	be	AUX
ajlm-823	23	16	important	important	ADJ
ajlm-823	23	17	for	for	ADP
ajlm-823	23	18	decreasing	decrease	VERB
ajlm-823	23	19	the	the	DET
ajlm-823	23	20	frequency	frequency	NOUN
ajlm-823	23	21	of	of	ADP
ajlm-823	23	22	alloimmunisation	alloimmunisation	NOUN
ajlm-823	23	23	and	and	CCONJ
ajlm-823	23	24	its	its	PRON
ajlm-823	23	25	associated	associated	ADJ
ajlm-823	23	26	complications6	complications6	NOUN
ajlm-823	23	27	.	.	PUNCT
ajlm-823	24	1	the	the	DET
ajlm-823	24	2	presence	presence	NOUN
ajlm-823	24	3	of	of	ADP
ajlm-823	24	4	alloantibodies	alloantibody	NOUN
ajlm-823	24	5	is	be	AUX
ajlm-823	24	6	a	a	DET
ajlm-823	24	7	major	major	ADJ
ajlm-823	24	8	complication	complication	NOUN
ajlm-823	24	9	in	in	ADP
ajlm-823	24	10	scd	scd	PROPN
ajlm-823	24	11	,	,	PUNCT
ajlm-823	24	12	presenting	present	VERB
ajlm-823	24	13	challenges	challenge	NOUN
ajlm-823	24	14	for	for	ADP
ajlm-823	24	15	medical	medical	ADJ
ajlm-823	24	16	management	management	NOUN
ajlm-823	24	17	.	.	PUNCT
ajlm-823	25	1	antigen	antigen	PROPN
ajlm-823	25	2	matching	match	VERB
ajlm-823	25	3	beyond	beyond	ADP
ajlm-823	25	4	the	the	DET
ajlm-823	25	5	standard	standard	ADJ
ajlm-823	25	6	abo	abo	NOUN
ajlm-823	25	7	blood	blood	NOUN
ajlm-823	25	8	grouping	group	VERB
ajlm-823	25	9	system	system	NOUN
ajlm-823	25	10	and	and	CCONJ
ajlm-823	25	11	rhesus	rhesus	NOUN
ajlm-823	25	12	typing	typing	NOUN
ajlm-823	25	13	has	have	AUX
ajlm-823	25	14	reduced	reduce	VERB
ajlm-823	25	15	complication	complication	NOUN
ajlm-823	25	16	rates.6	rates.6	PROPN
ajlm-823	25	17	according	accord	VERB
ajlm-823	25	18	to	to	ADP
ajlm-823	25	19	bashawri	bashawri	NOUN
ajlm-823	25	20	et	et	PROPN
ajlm-823	25	21	al	al	PROPN
ajlm-823	25	22	.	.	PROPN
ajlm-823	25	23	,	,	PUNCT
ajlm-823	25	24	race	race	NOUN
ajlm-823	25	25	and	and	CCONJ
ajlm-823	25	26	ethnicity	ethnicity	NOUN
ajlm-823	25	27	could	could	AUX
ajlm-823	25	28	be	be	AUX
ajlm-823	25	29	a	a	DET
ajlm-823	25	30	risk	risk	NOUN
ajlm-823	25	31	factor	factor	NOUN
ajlm-823	25	32	for	for	ADP
ajlm-823	25	33	alloimmunisation	alloimmunisation	NOUN
ajlm-823	25	34	in	in	ADP
ajlm-823	25	35	sickle	sickle	PROPN
ajlm-823	25	36	cell	cell	NOUN
ajlm-823	25	37	anaemia	anaemia	NOUN
ajlm-823	25	38	patients.7	patients.7	VERB
ajlm-823	25	39	additionally	additionally	ADV
ajlm-823	25	40	,	,	PUNCT
ajlm-823	25	41	failure	failure	NOUN
ajlm-823	25	42	to	to	PART
ajlm-823	25	43	screen	screen	VERB
ajlm-823	25	44	for	for	ADP
ajlm-823	25	45	minor	minor	ADJ
ajlm-823	25	46	antigens	antigen	NOUN
ajlm-823	25	47	such	such	ADJ
ajlm-823	25	48	as	as	ADP
ajlm-823	25	49	kidd	kidd	PROPN
ajlm-823	25	50	,	,	PUNCT
ajlm-823	25	51	duffy	duffy	PROPN
ajlm-823	25	52	,	,	PUNCT
ajlm-823	25	53	and	and	CCONJ
ajlm-823	25	54	mns	mns	PROPN
ajlm-823	25	55	blood	blood	NOUN
ajlm-823	25	56	groups	group	NOUN
ajlm-823	25	57	,	,	PUNCT
ajlm-823	25	58	might	might	AUX
ajlm-823	25	59	cause	cause	VERB
ajlm-823	25	60	a	a	DET
ajlm-823	25	61	mismatch	mismatch	NOUN
ajlm-823	25	62	and	and	CCONJ
ajlm-823	25	63	subsequent	subsequent	ADJ
ajlm-823	25	64	alloimmunisation	alloimmunisation	NOUN
ajlm-823	25	65	in	in	ADP
ajlm-823	25	66	blood	blood	NOUN
ajlm-823	25	67	recipients.8	recipients.8	PROPN
ajlm-823	25	68	.	.	PUNCT
ajlm-823	26	1	current	current	ADJ
ajlm-823	26	2	practice	practice	NOUN
ajlm-823	26	3	in	in	ADP
ajlm-823	26	4	tanzania	tanzania	PROPN
ajlm-823	26	5	is	be	AUX
ajlm-823	26	6	forward	forward	ADV
ajlm-823	26	7	grouping	group	VERB
ajlm-823	26	8	,	,	PUNCT
ajlm-823	26	9	which	which	PRON
ajlm-823	26	10	screens	screen	VERB
ajlm-823	26	11	for	for	ADP
ajlm-823	26	12	blood	blood	NOUN
ajlm-823	26	13	groups	group	NOUN
ajlm-823	26	14	abo	abo	VERB
ajlm-823	26	15	and	and	CCONJ
ajlm-823	26	16	rhesus	rhesus	NOUN
ajlm-823	26	17	d.	d.	PROPN
ajlm-823	26	18	however	however	ADV
ajlm-823	26	19	,	,	PUNCT
ajlm-823	26	20	there	there	PRON
ajlm-823	26	21	are	be	VERB
ajlm-823	26	22	currently	currently	ADV
ajlm-823	26	23	no	no	DET
ajlm-823	26	24	guidelines	guideline	NOUN
ajlm-823	26	25	for	for	ADP
ajlm-823	26	26	blood	blood	NOUN
ajlm-823	26	27	group	group	NOUN
ajlm-823	26	28	screening	screen	VERB
ajlm-823	26	29	at	at	ADP
ajlm-823	26	30	the	the	DET
ajlm-823	26	31	national	national	ADJ
ajlm-823	26	32	blood	blood	NOUN
ajlm-823	26	33	transfusion	transfusion	NOUN
ajlm-823	26	34	services	service	NOUN
ajlm-823	26	35	.	.	PUNCT
ajlm-823	27	1	thus	thus	ADV
ajlm-823	27	2	,	,	PUNCT
ajlm-823	27	3	patients	patient	NOUN
ajlm-823	27	4	are	be	AUX
ajlm-823	27	5	typically	typically	ADV
ajlm-823	27	6	transfused	transfuse	VERB
ajlm-823	27	7	without	without	ADP
ajlm-823	27	8	an	an	DET
ajlm-823	27	9	extensive	extensive	ADJ
ajlm-823	27	10	matching	matching	NOUN
ajlm-823	27	11	for	for	ADP
ajlm-823	27	12	compatibility	compatibility	NOUN
ajlm-823	27	13	.	.	PUNCT
ajlm-823	28	1	for	for	ADP
ajlm-823	28	2	example	example	NOUN
ajlm-823	28	3	,	,	PUNCT
ajlm-823	28	4	no	no	DET
ajlm-823	28	5	screening	screening	NOUN
ajlm-823	28	6	for	for	ADP
ajlm-823	28	7	kell	kell	PROPN
ajlm-823	28	8	antigens	antigen	NOUN
ajlm-823	28	9	is	be	AUX
ajlm-823	28	10	conducted	conduct	VERB
ajlm-823	28	11	.	.	PUNCT
ajlm-823	29	1	additionally	additionally	ADV
ajlm-823	29	2	,	,	PUNCT
ajlm-823	29	3	little	little	ADJ
ajlm-823	29	4	is	be	AUX
ajlm-823	29	5	known	know	VERB
ajlm-823	29	6	about	about	ADP
ajlm-823	29	7	the	the	DET
ajlm-823	29	8	extent	extent	NOUN
ajlm-823	29	9	to	to	PART
ajlm-823	29	10	which	which	PRON
ajlm-823	29	11	alloantibodies	alloantibody	NOUN
ajlm-823	29	12	affect	affect	VERB
ajlm-823	29	13	sickle	sickle	NOUN
ajlm-823	29	14	cell	cell	NOUN
ajlm-823	29	15	patients	patient	NOUN
ajlm-823	29	16	locally	locally	ADV
ajlm-823	29	17	.	.	PUNCT
ajlm-823	30	1	this	this	DET
ajlm-823	30	2	study	study	NOUN
ajlm-823	30	3	aimed	aim	VERB
ajlm-823	30	4	to	to	PART
ajlm-823	30	5	examine	examine	VERB
ajlm-823	30	6	the	the	DET
ajlm-823	30	7	prevalence	prevalence	NOUN
ajlm-823	30	8	of	of	ADP
ajlm-823	30	9	developing	develop	VERB
ajlm-823	30	10	red	red	ADJ
ajlm-823	30	11	blood	blood	NOUN
ajlm-823	30	12	cell	cell	NOUN
ajlm-823	30	13	alloimmunisation	alloimmunisation	NOUN
ajlm-823	30	14	among	among	ADP
ajlm-823	30	15	multiply	multiply	NOUN
ajlm-823	30	16	transfused	transfused	ADJ
ajlm-823	30	17	scd	scd	NOUN
ajlm-823	30	18	patients	patient	NOUN
ajlm-823	30	19	and	and	CCONJ
ajlm-823	30	20	identify	identify	VERB
ajlm-823	30	21	its	its	PRON
ajlm-823	30	22	associated	associated	ADJ
ajlm-823	30	23	risk	risk	NOUN
ajlm-823	30	24	factors	factor	NOUN
ajlm-823	30	25	,	,	PUNCT
ajlm-823	30	26	especially	especially	ADV
ajlm-823	30	27	in	in	ADP
ajlm-823	30	28	mwanza	mwanza	PROPN
ajlm-823	30	29	(	(	PUNCT
ajlm-823	30	30	lake	lake	NOUN
ajlm-823	30	31	zone	zone	PROPN
ajlm-823	30	32	)	)	PUNCT
ajlm-823	30	33	.	.	PUNCT
ajlm-823	31	1	this	this	PRON
ajlm-823	31	2	will	will	AUX
ajlm-823	31	3	,	,	PUNCT
ajlm-823	31	4	in	in	ADP
ajlm-823	31	5	turn	turn	NOUN
ajlm-823	31	6	,	,	PUNCT
ajlm-823	31	7	be	be	AUX
ajlm-823	31	8	valuable	valuable	ADJ
ajlm-823	31	9	for	for	ADP
ajlm-823	31	10	the	the	DET
ajlm-823	31	11	setting	setting	NOUN
ajlm-823	31	12	up	up	ADP
ajlm-823	31	13	of	of	ADP
ajlm-823	31	14	guidelines	guideline	NOUN
ajlm-823	31	15	for	for	ADP
ajlm-823	31	16	extensive	extensive	ADJ
ajlm-823	31	17	donor	donor	NOUN
ajlm-823	31	18	and	and	CCONJ
ajlm-823	31	19	recipient	recipient	NOUN
ajlm-823	31	20	typing	typing	NOUN
ajlm-823	31	21	,	,	PUNCT
ajlm-823	31	22	especially	especially	ADV
ajlm-823	31	23	for	for	ADP
ajlm-823	31	24	transfusion	transfusion	NOUN
ajlm-823	31	25	-	-	PUNCT
ajlm-823	31	26	dependent	dependent	ADJ
ajlm-823	31	27	patients	patient	NOUN
ajlm-823	31	28	at	at	ADP
ajlm-823	31	29	bugando	bugando	ADJ
ajlm-823	31	30	medical	medical	ADJ
ajlm-823	31	31	centre	centre	NOUN
ajlm-823	31	32	(	(	PUNCT
ajlm-823	31	33	bmc)/lake	bmc)/lake	NOUN
ajlm-823	31	34	zone	zone	NOUN
ajlm-823	31	35	national	national	ADJ
ajlm-823	31	36	blood	blood	NOUN
ajlm-823	31	37	transfusion	transfusion	NOUN
ajlm-823	31	38	services	service	NOUN
ajlm-823	31	39	laboratories	laboratory	NOUN
ajlm-823	31	40	.	.	PUNCT
ajlm-823	32	1	methods	method	NOUN
ajlm-823	32	2	ethical	ethical	ADJ
ajlm-823	32	3	considerations	consideration	NOUN
ajlm-823	32	4	ethical	ethical	ADJ
ajlm-823	32	5	clearance	clearance	NOUN
ajlm-823	32	6	was	be	AUX
ajlm-823	32	7	received	receive	VERB
ajlm-823	32	8	from	from	ADP
ajlm-823	32	9	the	the	DET
ajlm-823	32	10	catholic	catholic	PROPN
ajlm-823	32	11	university	university	PROPN
ajlm-823	32	12	of	of	ADP
ajlm-823	32	13	health	health	PROPN
ajlm-823	32	14	and	and	CCONJ
ajlm-823	32	15	allied	ally	VERB
ajlm-823	32	16	sciences	sciences	PROPN
ajlm-823	32	17	and	and	CCONJ
ajlm-823	32	18	bmc	bmc	ADJ
ajlm-823	32	19	joint	joint	ADJ
ajlm-823	32	20	research	research	NOUN
ajlm-823	32	21	committee	committee	NOUN
ajlm-823	32	22	(	(	PUNCT
ajlm-823	32	23	ethical	ethical	ADJ
ajlm-823	32	24	clearance	clearance	NOUN
ajlm-823	32	25	number	number	NOUN
ajlm-823	32	26	:	:	PUNCT
ajlm-823	32	27	323/2017	323/2017	NUM
ajlm-823	32	28	)	)	PUNCT
ajlm-823	32	29	.	.	PUNCT
ajlm-823	33	1	permission	permission	NOUN
ajlm-823	33	2	to	to	PART
ajlm-823	33	3	work	work	VERB
ajlm-823	33	4	in	in	ADP
ajlm-823	33	5	the	the	DET
ajlm-823	33	6	bmc	bmc	ADJ
ajlm-823	33	7	central	central	ADJ
ajlm-823	33	8	pathology	pathology	NOUN
ajlm-823	33	9	laboratory	laboratory	NOUN
ajlm-823	33	10	was	be	AUX
ajlm-823	33	11	also	also	ADV
ajlm-823	33	12	sought	seek	VERB
ajlm-823	33	13	from	from	ADP
ajlm-823	33	14	the	the	DET
ajlm-823	33	15	laboratory	laboratory	NOUN
ajlm-823	33	16	director	director	NOUN
ajlm-823	33	17	and	and	CCONJ
ajlm-823	33	18	manager	manager	NOUN
ajlm-823	33	19	.	.	PUNCT
ajlm-823	34	1	written	write	VERB
ajlm-823	34	2	informed	informed	ADJ
ajlm-823	34	3	consent	consent	NOUN
ajlm-823	34	4	was	be	AUX
ajlm-823	34	5	sought	seek	VERB
ajlm-823	34	6	from	from	ADP
ajlm-823	34	7	both	both	CCONJ
ajlm-823	34	8	inpatient	inpatient	PROPN
ajlm-823	34	9	and	and	CCONJ
ajlm-823	34	10	outpatient	outpatient	NOUN
ajlm-823	34	11	scd	scd	NOUN
ajlm-823	34	12	with	with	ADP
ajlm-823	34	13	multiple	multiple	ADJ
ajlm-823	34	14	transfusions	transfusion	NOUN
ajlm-823	34	15	before	before	ADP
ajlm-823	34	16	including	include	VERB
ajlm-823	34	17	them	they	PRON
ajlm-823	34	18	in	in	ADP
ajlm-823	34	19	the	the	DET
ajlm-823	34	20	study	study	NOUN
ajlm-823	34	21	.	.	PUNCT
ajlm-823	35	1	study	study	NOUN
ajlm-823	35	2	design	design	NOUN
ajlm-823	35	3	this	this	PRON
ajlm-823	35	4	was	be	AUX
ajlm-823	35	5	a	a	DET
ajlm-823	35	6	cross	cross	ADJ
ajlm-823	35	7	-	-	ADJ
ajlm-823	35	8	sectional	sectional	ADJ
ajlm-823	35	9	study	study	NOUN
ajlm-823	35	10	conducted	conduct	VERB
ajlm-823	35	11	from	from	ADP
ajlm-823	35	12	may	may	PROPN
ajlm-823	35	13	2017	2017	NUM
ajlm-823	35	14	to	to	ADP
ajlm-823	35	15	july	july	PROPN
ajlm-823	35	16	2017	2017	NUM
ajlm-823	35	17	at	at	ADP
ajlm-823	35	18	the	the	DET
ajlm-823	35	19	bmc	bmc	PROPN
ajlm-823	35	20	,	,	PUNCT
ajlm-823	35	21	mwanza	mwanza	ADJ
ajlm-823	35	22	city	city	NOUN
ajlm-823	35	23	(	(	PUNCT
ajlm-823	35	24	lake	lake	NOUN
ajlm-823	35	25	zone	zone	PROPN
ajlm-823	35	26	)	)	PUNCT
ajlm-823	35	27	,	,	PUNCT
ajlm-823	35	28	tanzania	tanzania	PROPN
ajlm-823	35	29	.	.	PUNCT
ajlm-823	36	1	participants	participant	NOUN
ajlm-823	36	2	were	be	AUX
ajlm-823	36	3	inpatients	inpatient	NOUN
ajlm-823	36	4	and	and	CCONJ
ajlm-823	36	5	outpatients	outpatient	NOUN
ajlm-823	36	6	with	with	ADP
ajlm-823	36	7	scd	scd	PROPN
ajlm-823	36	8	who	who	PRON
ajlm-823	36	9	attended	attend	VERB
ajlm-823	36	10	the	the	DET
ajlm-823	36	11	bmc	bmc	NOUN
ajlm-823	36	12	during	during	ADP
ajlm-823	36	13	the	the	DET
ajlm-823	36	14	study	study	NOUN
ajlm-823	36	15	period	period	NOUN
ajlm-823	36	16	and	and	CCONJ
ajlm-823	36	17	consented	consent	VERB
ajlm-823	36	18	to	to	PART
ajlm-823	36	19	participate	participate	VERB
ajlm-823	36	20	.	.	PUNCT
ajlm-823	37	1	patients	patient	NOUN
ajlm-823	37	2	were	be	AUX
ajlm-823	37	3	recruited	recruit	VERB
ajlm-823	37	4	until	until	SCONJ
ajlm-823	37	5	the	the	DET
ajlm-823	37	6	estimated	estimate	VERB
ajlm-823	37	7	minimum	minimum	ADJ
ajlm-823	37	8	sample	sample	NOUN
ajlm-823	37	9	size	size	NOUN
ajlm-823	37	10	of	of	ADP
ajlm-823	37	11	200	200	NUM
ajlm-823	37	12	scd	scd	NOUN
ajlm-823	37	13	patients	patient	NOUN
ajlm-823	37	14	was	be	AUX
ajlm-823	37	15	reached	reach	VERB
ajlm-823	37	16	;	;	PUNCT
ajlm-823	37	17	the	the	DET
ajlm-823	37	18	sample	sample	NOUN
ajlm-823	37	19	size	size	NOUN
ajlm-823	37	20	was	be	AUX
ajlm-823	37	21	estimated	estimate	VERB
ajlm-823	37	22	using	use	VERB
ajlm-823	37	23	the	the	DET
ajlm-823	37	24	kishi	kishi	PROPN
ajlm-823	37	25	lisle	lisle	PROPN
ajlm-823	37	26	formula	formula	NOUN
ajlm-823	37	27	.	.	PUNCT
ajlm-823	38	1	the	the	DET
ajlm-823	38	2	study	study	NOUN
ajlm-823	38	3	included	include	VERB
ajlm-823	38	4	all	all	DET
ajlm-823	38	5	scd	scd	NOUN
ajlm-823	38	6	patients	patient	NOUN
ajlm-823	38	7	attending	attend	VERB
ajlm-823	38	8	bmc	bmc	ADJ
ajlm-823	38	9	inpatient	inpatient	NOUN
ajlm-823	38	10	and	and	CCONJ
ajlm-823	38	11	outpatient	outpatient	NOUN
ajlm-823	38	12	departments	department	NOUN
ajlm-823	38	13	for	for	ADP
ajlm-823	38	14	transfusion	transfusion	NOUN
ajlm-823	38	15	therapy	therapy	NOUN
ajlm-823	38	16	purposes	purpose	NOUN
ajlm-823	38	17	who	who	PRON
ajlm-823	38	18	had	have	AUX
ajlm-823	38	19	received	receive	VERB
ajlm-823	38	20	at	at	ADP
ajlm-823	38	21	least	least	ADV
ajlm-823	38	22	two	two	NUM
ajlm-823	38	23	units	unit	NOUN
ajlm-823	38	24	of	of	ADP
ajlm-823	38	25	blood	blood	NOUN
ajlm-823	38	26	during	during	ADP
ajlm-823	38	27	the	the	DET
ajlm-823	38	28	previous	previous	ADJ
ajlm-823	38	29	year	year	NOUN
ajlm-823	38	30	the	the	DET
ajlm-823	38	31	study	study	NOUN
ajlm-823	38	32	excluded	exclude	VERB
ajlm-823	38	33	patients	patient	NOUN
ajlm-823	38	34	with	with	ADP
ajlm-823	38	35	no	no	DET
ajlm-823	38	36	blood	blood	NOUN
ajlm-823	38	37	transfusion	transfusion	NOUN
ajlm-823	38	38	history	history	NOUN
ajlm-823	38	39	and	and	CCONJ
ajlm-823	38	40	patients	patient	NOUN
ajlm-823	38	41	who	who	PRON
ajlm-823	38	42	did	do	AUX
ajlm-823	38	43	not	not	PART
ajlm-823	38	44	consent	consent	VERB
ajlm-823	38	45	to	to	PART
ajlm-823	38	46	participate	participate	VERB
ajlm-823	38	47	.	.	PUNCT
ajlm-823	39	1	a	a	DET
ajlm-823	39	2	structured	structured	ADJ
ajlm-823	39	3	questionnaire	questionnaire	NOUN
ajlm-823	39	4	was	be	AUX
ajlm-823	39	5	completed	complete	VERB
ajlm-823	39	6	by	by	ADP
ajlm-823	39	7	the	the	DET
ajlm-823	39	8	parent	parent	NOUN
ajlm-823	39	9	or	or	CCONJ
ajlm-823	39	10	guardian	guardian	NOUN
ajlm-823	39	11	of	of	ADP
ajlm-823	39	12	the	the	DET
ajlm-823	39	13	child	child	NOUN
ajlm-823	39	14	and	and	CCONJ
ajlm-823	39	15	laboratory	laboratory	NOUN
ajlm-823	39	16	records	record	NOUN
ajlm-823	39	17	confirmed	confirm	VERB
ajlm-823	39	18	scd	scd	NOUN
ajlm-823	39	19	,	,	PUNCT
ajlm-823	39	20	number	number	NOUN
ajlm-823	39	21	of	of	ADP
ajlm-823	39	22	transfusions	transfusion	NOUN
ajlm-823	39	23	and	and	CCONJ
ajlm-823	39	24	interval	interval	NOUN
ajlm-823	39	25	of	of	ADP
ajlm-823	39	26	blood	blood	NOUN
ajlm-823	39	27	transfusion	transfusion	NOUN
ajlm-823	39	28	.	.	PUNCT
ajlm-823	40	1	the	the	DET
ajlm-823	40	2	questionnaire	questionnaire	NOUN
ajlm-823	40	3	was	be	AUX
ajlm-823	40	4	used	use	VERB
ajlm-823	40	5	to	to	PART
ajlm-823	40	6	gather	gather	VERB
ajlm-823	40	7	the	the	DET
ajlm-823	40	8	demographic	demographic	ADJ
ajlm-823	40	9	and	and	CCONJ
ajlm-823	40	10	medical	medical	ADJ
ajlm-823	40	11	history	history	NOUN
ajlm-823	40	12	information	information	NOUN
ajlm-823	40	13	of	of	ADP
ajlm-823	40	14	selected	select	VERB
ajlm-823	40	15	participants	participant	NOUN
ajlm-823	40	16	.	.	PUNCT
ajlm-823	41	1	sample	sample	NOUN
ajlm-823	41	2	collection	collection	NOUN
ajlm-823	41	3	one	one	NUM
ajlm-823	41	4	4	4	NUM
ajlm-823	41	5	-	-	PUNCT
ajlm-823	41	6	ml	ml	NOUN
ajlm-823	41	7	blood	blood	NOUN
ajlm-823	41	8	sample	sample	NOUN
ajlm-823	41	9	was	be	AUX
ajlm-823	41	10	collected	collect	VERB
ajlm-823	41	11	from	from	ADP
ajlm-823	41	12	each	each	DET
ajlm-823	41	13	patient	patient	NOUN
ajlm-823	41	14	by	by	ADP
ajlm-823	41	15	phlebotomists	phlebotomist	NOUN
ajlm-823	41	16	at	at	ADP
ajlm-823	41	17	the	the	DET
ajlm-823	41	18	central	central	ADJ
ajlm-823	41	19	pathology	pathology	NOUN
ajlm-823	41	20	laboratory	laboratory	NOUN
ajlm-823	41	21	at	at	ADP
ajlm-823	41	22	bmc	bmc	PROPN
ajlm-823	41	23	into	into	ADP
ajlm-823	41	24	ethyldiammine	ethyldiammine	NOUN
ajlm-823	41	25	tetraacetate	tetraacetate	NOUN
ajlm-823	41	26	tubes	tube	NOUN
ajlm-823	41	27	to	to	PART
ajlm-823	41	28	avoid	avoid	VERB
ajlm-823	41	29	agglutination	agglutination	NOUN
ajlm-823	41	30	and	and	CCONJ
ajlm-823	41	31	preserve	preserve	VERB
ajlm-823	41	32	red	red	ADJ
ajlm-823	41	33	blood	blood	NOUN
ajlm-823	41	34	cell	cell	NOUN
ajlm-823	41	35	(	(	PUNCT
ajlm-823	41	36	rbc	rbc	PROPN
ajlm-823	41	37	)	)	PUNCT
ajlm-823	41	38	antigenicity	antigenicity	NOUN
ajlm-823	41	39	.	.	PUNCT
ajlm-823	42	1	samples	sample	NOUN
ajlm-823	42	2	were	be	AUX
ajlm-823	42	3	stored	store	VERB
ajlm-823	42	4	at	at	ADP
ajlm-823	42	5	2	2	NUM
ajlm-823	42	6	°	°	ADP
ajlm-823	42	7	c	c	NOUN
ajlm-823	42	8	–	–	PUNCT
ajlm-823	42	9	6	6	NUM
ajlm-823	42	10	°	°	ADP
ajlm-823	42	11	c	c	NOUN
ajlm-823	42	12	refrigeration	refrigeration	NOUN
ajlm-823	42	13	for	for	ADP
ajlm-823	42	14	not	not	PART
ajlm-823	42	15	more	more	ADJ
ajlm-823	42	16	than	than	ADP
ajlm-823	42	17	3	3	NUM
ajlm-823	42	18	days	day	NOUN
ajlm-823	42	19	.	.	PUNCT
ajlm-823	43	1	laboratory	laboratory	NOUN
ajlm-823	43	2	analysis	analysis	NOUN
ajlm-823	43	3	alloantiboy	alloantiboy	NOUN
ajlm-823	43	4	detection	detection	NOUN
ajlm-823	43	5	–	–	PUNCT
ajlm-823	43	6	indirect	indirect	ADJ
ajlm-823	43	7	coombs	coombs	PROPN
ajlm-823	43	8	test	test	NOUN
ajlm-823	43	9	the	the	DET
ajlm-823	43	10	presence	presence	NOUN
ajlm-823	43	11	of	of	ADP
ajlm-823	43	12	alloantibodies	alloantibody	NOUN
ajlm-823	43	13	was	be	AUX
ajlm-823	43	14	determined	determine	VERB
ajlm-823	43	15	by	by	ADP
ajlm-823	43	16	assessing	assess	VERB
ajlm-823	43	17	antigen	antigen	NOUN
ajlm-823	43	18	-	-	PUNCT
ajlm-823	43	19	antibody	antibody	NOUN
ajlm-823	43	20	agglutination	agglutination	NOUN
ajlm-823	43	21	in	in	ADP
ajlm-823	43	22	patient	patient	ADJ
ajlm-823	43	23	serum	serum	NOUN
ajlm-823	43	24	where	where	SCONJ
ajlm-823	43	25	agglutination	agglutination	NOUN
ajlm-823	43	26	indicates	indicate	VERB
ajlm-823	43	27	incompatibility	incompatibility	NOUN
ajlm-823	43	28	of	of	ADP
ajlm-823	43	29	patient	patient	NOUN
ajlm-823	43	30	’s	’s	PART
ajlm-823	43	31	serum	serum	NOUN
ajlm-823	43	32	antibodies	antibody	NOUN
ajlm-823	43	33	with	with	ADP
ajlm-823	43	34	commercially	commercially	ADV
ajlm-823	43	35	purchased	purchase	VERB
ajlm-823	43	36	red	red	ADJ
ajlm-823	43	37	cells	cell	NOUN
ajlm-823	43	38	.	.	PUNCT
ajlm-823	44	1	three	three	NUM
ajlm-823	44	2	commercially	commercially	ADV
ajlm-823	44	3	purchased	purchase	VERB
ajlm-823	44	4	red	red	ADJ
ajlm-823	44	5	cell	cell	NOUN
ajlm-823	44	6	-	-	PUNCT
ajlm-823	44	7	antibody	antibody	NOUN
ajlm-823	44	8	screening	screening	NOUN
ajlm-823	44	9	cell	cell	NOUN
ajlm-823	44	10	panels	panel	NOUN
ajlm-823	44	11	were	be	AUX
ajlm-823	44	12	used	use	VERB
ajlm-823	44	13	for	for	ADP
ajlm-823	44	14	screening	screen	VERB
ajlm-823	44	15	the	the	DET
ajlm-823	44	16	parted	part	VERB
ajlm-823	44	17	blood	blood	NOUN
ajlm-823	44	18	cells	cell	NOUN
ajlm-823	44	19	(	(	PUNCT
ajlm-823	44	20	screen	screen	NOUN
ajlm-823	44	21	cell	cell	NOUN
ajlm-823	44	22	1	1	NUM
ajlm-823	44	23	,	,	PUNCT
ajlm-823	44	24	product	product	NOUN
ajlm-823	44	25	code	code	NOUN
ajlm-823	44	26	r1wr1	r1wr1	NOUN
ajlm-823	44	27	;	;	PUNCT
ajlm-823	44	28	screen	screen	NOUN
ajlm-823	44	29	cell	cell	NOUN
ajlm-823	44	30	2	2	NUM
ajlm-823	44	31	,	,	PUNCT
ajlm-823	44	32	product	product	NOUN
ajlm-823	44	33	code	code	NOUN
ajlm-823	44	34	r2r2	r2r2	NOUN
ajlm-823	44	35	;	;	PUNCT
ajlm-823	44	36	and	and	CCONJ
ajlm-823	44	37	screen	screen	NOUN
ajlm-823	44	38	cell	cell	NOUN
ajlm-823	44	39	3	3	NUM
ajlm-823	44	40	,	,	PUNCT
ajlm-823	44	41	product	product	NOUN
ajlm-823	44	42	code	code	PROPN
ajlm-823	44	43	rr	rr	PROPN
ajlm-823	44	44	)	)	PUNCT
ajlm-823	44	45	(	(	PUNCT
ajlm-823	44	46	lorne	lorne	PROPN
ajlm-823	44	47	laboratories	laboratory	NOUN
ajlm-823	44	48	,	,	PUNCT
ajlm-823	44	49	reading	reading	NOUN
ajlm-823	44	50	,	,	PUNCT
ajlm-823	44	51	berkshire	berkshire	NOUN
ajlm-823	44	52	,	,	PUNCT
ajlm-823	44	53	united	united	ADJ
ajlm-823	44	54	kingdom	kingdom	PROPN
ajlm-823	44	55	)	)	PUNCT
ajlm-823	44	56	.	.	PUNCT
ajlm-823	45	1	screening	screen	VERB
ajlm-823	45	2	for	for	ADP
ajlm-823	45	3	the	the	DET
ajlm-823	45	4	different	different	ADJ
ajlm-823	45	5	rbcs	rbcs	NOUN
ajlm-823	45	6	antigens	antigen	NOUN
ajlm-823	45	7	was	be	AUX
ajlm-823	45	8	done	do	VERB
ajlm-823	45	9	as	as	SCONJ
ajlm-823	45	10	described	describe	VERB
ajlm-823	45	11	by	by	ADP
ajlm-823	45	12	the	the	DET
ajlm-823	45	13	manufacturer	manufacturer	NOUN
ajlm-823	45	14	.	.	PUNCT
ajlm-823	46	1	screen	screen	NOUN
ajlm-823	46	2	cell	cell	NOUN
ajlm-823	46	3	1	1	NUM
ajlm-823	46	4	had	have	VERB
ajlm-823	46	5	c	c	NOUN
ajlm-823	46	6	,	,	PUNCT
ajlm-823	46	7	d	d	NOUN
ajlm-823	46	8	,	,	PUNCT
ajlm-823	46	9	e	e	NOUN
ajlm-823	46	10	,	,	PUNCT
ajlm-823	46	11	cw	cw	NOUN
ajlm-823	46	12	,	,	PUNCT
ajlm-823	46	13	m	m	PROPN
ajlm-823	46	14	,	,	PUNCT
ajlm-823	46	15	n	n	CCONJ
ajlm-823	46	16	,	,	PUNCT
ajlm-823	46	17	s	s	PROPN
ajlm-823	46	18	,	,	PUNCT
ajlm-823	46	19	p1	p1	PROPN
ajlm-823	46	20	,	,	PUNCT
ajlm-823	46	21	k	k	PROPN
ajlm-823	46	22	,	,	PUNCT
ajlm-823	46	23	k	k	PROPN
ajlm-823	46	24	,	,	PUNCT
ajlm-823	46	25	leb	leb	PROPN
ajlm-823	46	26	,	,	PUNCT
ajlm-823	46	27	fya	fya	PROPN
ajlm-823	46	28	,	,	PUNCT
ajlm-823	46	29	jka	jka	PROPN
ajlm-823	46	30	,	,	PUNCT
ajlm-823	46	31	and	and	CCONJ
ajlm-823	46	32	jkb	jkb	NOUN
ajlm-823	46	33	red	red	ADJ
ajlm-823	46	34	cells	cell	NOUN
ajlm-823	46	35	.	.	PUNCT
ajlm-823	47	1	screen	screen	NOUN
ajlm-823	47	2	cell	cell	NOUN
ajlm-823	47	3	2	2	NUM
ajlm-823	47	4	had	have	VERB
ajlm-823	47	5	d	d	NOUN
ajlm-823	47	6	,	,	PUNCT
ajlm-823	47	7	e	e	NOUN
ajlm-823	47	8	,	,	PUNCT
ajlm-823	47	9	c	c	X
ajlm-823	47	10	,	,	PUNCT
ajlm-823	47	11	m	m	PROPN
ajlm-823	47	12	,	,	PUNCT
ajlm-823	47	13	s	s	PROPN
ajlm-823	47	14	,	,	PUNCT
ajlm-823	47	15	p1	p1	PROPN
ajlm-823	47	16	,	,	PUNCT
ajlm-823	47	17	k	k	PROPN
ajlm-823	47	18	,	,	PUNCT
ajlm-823	47	19	leb	leb	PROPN
ajlm-823	47	20	,	,	PUNCT
ajlm-823	47	21	fyb	fyb	ADJ
ajlm-823	47	22	,	,	PUNCT
ajlm-823	47	23	and	and	CCONJ
ajlm-823	47	24	jkb	jkb	NOUN
ajlm-823	47	25	red	red	ADJ
ajlm-823	47	26	cells	cell	NOUN
ajlm-823	47	27	,	,	PUNCT
ajlm-823	47	28	and	and	CCONJ
ajlm-823	47	29	screen	screen	NOUN
ajlm-823	47	30	cell	cell	NOUN
ajlm-823	47	31	3	3	NUM
ajlm-823	47	32	had	have	VERB
ajlm-823	47	33	c	c	NOUN
ajlm-823	47	34	,	,	PUNCT
ajlm-823	47	35	e	e	NOUN
ajlm-823	47	36	,	,	PUNCT
ajlm-823	47	37	n	n	CCONJ
ajlm-823	47	38	,	,	PUNCT
ajlm-823	47	39	s	s	PROPN
ajlm-823	47	40	,	,	PUNCT
ajlm-823	47	41	p1	p1	PROPN
ajlm-823	47	42	,	,	PUNCT
ajlm-823	47	43	k	k	PROPN
ajlm-823	47	44	,	,	PUNCT
ajlm-823	47	45	kpa	kpa	PROPN
ajlm-823	47	46	,	,	PUNCT
ajlm-823	47	47	lea	lea	PROPN
ajlm-823	47	48	,	,	PUNCT
ajlm-823	47	49	fyb	fyb	ADJ
ajlm-823	47	50	,	,	PUNCT
ajlm-823	47	51	and	and	CCONJ
ajlm-823	47	52	jka	jka	PROPN
ajlm-823	47	53	red	red	PROPN
ajlm-823	47	54	cells	cell	NOUN
ajlm-823	47	55	(	(	PUNCT
ajlm-823	47	56	table	table	NOUN
ajlm-823	47	57	1	1	NUM
ajlm-823	47	58	)	)	PUNCT
ajlm-823	47	59	.	.	PUNCT
ajlm-823	48	1	a	a	DET
ajlm-823	48	2	mixture	mixture	NOUN
ajlm-823	48	3	of	of	ADP
ajlm-823	48	4	patient	patient	ADJ
ajlm-823	48	5	serum	serum	NOUN
ajlm-823	48	6	and	and	CCONJ
ajlm-823	48	7	the	the	DET
ajlm-823	48	8	commercial	commercial	ADJ
ajlm-823	48	9	red	red	ADJ
ajlm-823	48	10	cell	cell	NOUN
ajlm-823	48	11	-	-	PUNCT
ajlm-823	48	12	antibody	antibody	NOUN
ajlm-823	48	13	screening	screen	VERB
ajlm-823	48	14	cells	cell	NOUN
ajlm-823	48	15	was	be	AUX
ajlm-823	48	16	centrifuged	centrifuge	VERB
ajlm-823	48	17	for	for	ADP
ajlm-823	48	18	10	10	NUM
ajlm-823	48	19	minutes	minute	NOUN
ajlm-823	48	20	at	at	ADP
ajlm-823	48	21	room	room	NOUN
ajlm-823	48	22	temperature	temperature	NOUN
ajlm-823	48	23	(	(	PUNCT
ajlm-823	48	24	25	25	NUM
ajlm-823	48	25	°	°	NOUN
ajlm-823	48	26	c	c	NOUN
ajlm-823	48	27	)	)	PUNCT
ajlm-823	48	28	.	.	PUNCT
ajlm-823	49	1	tubes	tube	NOUN
ajlm-823	49	2	were	be	AUX
ajlm-823	49	3	checked	check	VERB
ajlm-823	49	4	for	for	ADP
ajlm-823	49	5	agglutination	agglutination	NOUN
ajlm-823	49	6	confirming	confirm	VERB
ajlm-823	49	7	cold	cold	ADJ
ajlm-823	49	8	alloantibodies	alloantibody	NOUN
ajlm-823	49	9	(	(	PUNCT
ajlm-823	49	10	immunoglobulin	immunoglobulin	NOUN
ajlm-823	49	11	m	m	PROPN
ajlm-823	49	12	)	)	PUNCT
ajlm-823	49	13	.	.	PUNCT
ajlm-823	50	1	then	then	ADV
ajlm-823	50	2	low	low	ADJ
ajlm-823	50	3	ionic	ionic	ADJ
ajlm-823	50	4	strength	strength	NOUN
ajlm-823	50	5	solution	solution	NOUN
ajlm-823	50	6	was	be	AUX
ajlm-823	50	7	added	add	VERB
ajlm-823	50	8	to	to	PART
ajlm-823	50	9	enhance	enhance	VERB
ajlm-823	50	10	antigen	antigen	NOUN
ajlm-823	50	11	-	-	PUNCT
ajlm-823	50	12	antibody	antibody	NOUN
ajlm-823	50	13	reaction	reaction	NOUN
ajlm-823	50	14	,	,	PUNCT
ajlm-823	50	15	followed	follow	VERB
ajlm-823	50	16	by	by	ADP
ajlm-823	50	17	incubation	incubation	NOUN
ajlm-823	50	18	at	at	ADP
ajlm-823	50	19	37	37	NUM
ajlm-823	50	20	°	°	NOUN
ajlm-823	50	21	c	c	NOUN
ajlm-823	50	22	for	for	SCONJ
ajlm-823	50	23	15	15	NUM
ajlm-823	50	24	min	min	NOUN
ajlm-823	50	25	to	to	PART
ajlm-823	50	26	detect	detect	VERB
ajlm-823	50	27	warm	warm	ADJ
ajlm-823	50	28	antibodies	antibody	NOUN
ajlm-823	50	29	.	.	PUNCT
ajlm-823	51	1	after	after	ADP
ajlm-823	51	2	incubation	incubation	NOUN
ajlm-823	51	3	,	,	PUNCT
ajlm-823	51	4	a	a	DET
ajlm-823	51	5	cell	cell	NOUN
ajlm-823	51	6	wash	wash	NOUN
ajlm-823	51	7	was	be	AUX
ajlm-823	51	8	done	do	VERB
ajlm-823	51	9	by	by	ADP
ajlm-823	51	10	using	use	VERB
ajlm-823	51	11	a	a	DET
ajlm-823	51	12	washing	washing	NOUN
ajlm-823	51	13	buffer	buffer	NOUN
ajlm-823	51	14	to	to	PART
ajlm-823	51	15	remove	remove	VERB
ajlm-823	51	16	unbounded	unbounded	ADJ
ajlm-823	51	17	antibodies	antibody	NOUN
ajlm-823	51	18	.	.	PUNCT
ajlm-823	52	1	finally	finally	ADV
ajlm-823	52	2	,	,	PUNCT
ajlm-823	52	3	anti	anti	ADJ
ajlm-823	52	4	-	-	ADJ
ajlm-823	52	5	human	human	ADJ
ajlm-823	52	6	globulin	globulin	NOUN
ajlm-823	52	7	(	(	PUNCT
ajlm-823	52	8	coombs	coombs	PROPN
ajlm-823	52	9	reagent	reagent	NOUN
ajlm-823	52	10	)	)	PUNCT
ajlm-823	52	11	was	be	AUX
ajlm-823	52	12	added	add	VERB
ajlm-823	52	13	to	to	ADP
ajlm-823	52	14	the	the	DET
ajlm-823	52	15	tubes	tube	NOUN
ajlm-823	52	16	to	to	PART
ajlm-823	52	17	detect	detect	VERB
ajlm-823	52	18	the	the	DET
ajlm-823	52	19	presence	presence	NOUN
ajlm-823	52	20	of	of	ADP
ajlm-823	52	21	alloantibodies	alloantibody	NOUN
ajlm-823	52	22	.	.	PUNCT
ajlm-823	53	1	the	the	DET
ajlm-823	53	2	tubes	tube	NOUN
ajlm-823	53	3	were	be	AUX
ajlm-823	53	4	then	then	ADV
ajlm-823	53	5	centrifuged	centrifuge	VERB
ajlm-823	53	6	at	at	ADP
ajlm-823	53	7	1500	1500	NUM
ajlm-823	53	8	revolutions	revolution	NOUN
ajlm-823	53	9	per	per	ADP
ajlm-823	53	10	minute	minute	NOUN
ajlm-823	53	11	for	for	ADP
ajlm-823	53	12	3	3	NUM
ajlm-823	53	13	min	min	NOUN
ajlm-823	53	14	.	.	PUNCT
ajlm-823	54	1	the	the	DET
ajlm-823	54	2	centrifuged	centrifuged	ADJ
ajlm-823	54	3	mixture	mixture	NOUN
ajlm-823	54	4	of	of	ADP
ajlm-823	54	5	patient	patient	ADJ
ajlm-823	54	6	serum	serum	NOUN
ajlm-823	54	7	,	,	PUNCT
ajlm-823	54	8	commercial	commercial	ADJ
ajlm-823	54	9	red	red	ADJ
ajlm-823	54	10	cells	cell	NOUN
ajlm-823	54	11	and	and	CCONJ
ajlm-823	54	12	anti	anti	ADJ
ajlm-823	54	13	-	-	ADJ
ajlm-823	54	14	human	human	ADJ
ajlm-823	54	15	globulin	globulin	NOUN
ajlm-823	54	16	was	be	AUX
ajlm-823	54	17	read	read	VERB
ajlm-823	54	18	microscopically	microscopically	ADV
ajlm-823	54	19	to	to	PART
ajlm-823	54	20	assess	assess	VERB
ajlm-823	54	21	the	the	DET
ajlm-823	54	22	presence	presence	NOUN
ajlm-823	54	23	of	of	ADP
ajlm-823	54	24	agglutination	agglutination	NOUN
ajlm-823	54	25	.	.	PUNCT
ajlm-823	55	1	tubes	tube	NOUN
ajlm-823	55	2	with	with	ADP
ajlm-823	55	3	agglutination	agglutination	NOUN
ajlm-823	55	4	were	be	AUX
ajlm-823	55	5	considered	consider	VERB
ajlm-823	55	6	‘	'	PUNCT
ajlm-823	55	7	positive	positive	ADJ
ajlm-823	55	8	’	'	PUNCT
ajlm-823	55	9	,	,	PUNCT
ajlm-823	55	10	whereas	whereas	SCONJ
ajlm-823	55	11	tubes	tube	NOUN
ajlm-823	55	12	with	with	ADP
ajlm-823	55	13	no	no	DET
ajlm-823	55	14	agglutination	agglutination	NOUN
ajlm-823	55	15	were	be	AUX
ajlm-823	55	16	considered	consider	VERB
ajlm-823	55	17	‘	'	PUNCT
ajlm-823	55	18	negative	negative	ADJ
ajlm-823	55	19	’	'	PUNCT
ajlm-823	55	20	.	.	PUNCT
ajlm-823	56	1	agglutination	agglutination	NOUN
ajlm-823	56	2	was	be	AUX
ajlm-823	56	3	classified	classify	VERB
ajlm-823	56	4	as	as	ADP
ajlm-823	56	5	‘	'	PUNCT
ajlm-823	56	6	strong	strong	ADJ
ajlm-823	56	7	’	'	PUNCT
ajlm-823	56	8	when	when	SCONJ
ajlm-823	56	9	agglutination	agglutination	NOUN
ajlm-823	56	10	could	could	AUX
ajlm-823	56	11	be	be	AUX
ajlm-823	56	12	seen	see	VERB
ajlm-823	56	13	macroscopically	macroscopically	ADV
ajlm-823	56	14	or	or	CCONJ
ajlm-823	56	15	as	as	ADP
ajlm-823	56	16	‘	'	PUNCT
ajlm-823	56	17	mild	mild	ADJ
ajlm-823	56	18	’	'	PUNCT
ajlm-823	56	19	when	when	SCONJ
ajlm-823	56	20	agglutination	agglutination	NOUN
ajlm-823	56	21	could	could	AUX
ajlm-823	56	22	only	only	ADV
ajlm-823	56	23	be	be	AUX
ajlm-823	56	24	confirmed	confirm	VERB
ajlm-823	56	25	microscopically	microscopically	ADV
ajlm-823	56	26	.	.	PUNCT
ajlm-823	57	1	alloantibodies	alloantibody	NOUN
ajlm-823	57	2	were	be	AUX
ajlm-823	57	3	then	then	ADV
ajlm-823	57	4	classified	classify	VERB
ajlm-823	57	5	as	as	ADP
ajlm-823	57	6	‘	'	PUNCT
ajlm-823	57	7	warm	warm	ADJ
ajlm-823	57	8	’	'	PUNCT
ajlm-823	57	9	alloantibodies	alloantibody	NOUN
ajlm-823	57	10	(	(	PUNCT
ajlm-823	57	11	antibodies	antibodie	VERB
ajlm-823	57	12	that	that	PRON
ajlm-823	57	13	react	react	VERB
ajlm-823	57	14	at	at	ADP
ajlm-823	57	15	or	or	CCONJ
ajlm-823	57	16	near	near	ADP
ajlm-823	57	17	37	37	NUM
ajlm-823	57	18	°	°	NOUN
ajlm-823	57	19	c	c	NOUN
ajlm-823	57	20	)	)	PUNCT
ajlm-823	57	21	or	or	CCONJ
ajlm-823	57	22	as	as	ADP
ajlm-823	57	23	‘	'	PUNCT
ajlm-823	57	24	cold	cold	ADJ
ajlm-823	57	25	’	'	PUNCT
ajlm-823	57	26	alloantibodies	alloantibody	NOUN
ajlm-823	57	27	(	(	PUNCT
ajlm-823	57	28	antibodies	antibodie	VERB
ajlm-823	57	29	that	that	PRON
ajlm-823	57	30	react	react	VERB
ajlm-823	57	31	below	below	ADP
ajlm-823	57	32	37	37	NUM
ajlm-823	57	33	°	°	NOUN
ajlm-823	57	34	c	c	NOUN
ajlm-823	57	35	)	)	PUNCT
ajlm-823	57	36	.	.	PUNCT
ajlm-823	58	1	table	table	NOUN
ajlm-823	58	2	1	1	NUM
ajlm-823	58	3	:	:	PUNCT
ajlm-823	58	4	 	 	SPACE
ajlm-823	58	5	screening	screen	VERB
ajlm-823	58	6	cells	cell	NOUN
ajlm-823	58	7	used	use	VERB
ajlm-823	58	8	and	and	CCONJ
ajlm-823	58	9	blood	blood	NOUN
ajlm-823	58	10	groups	group	NOUN
ajlm-823	58	11	tested	test	VERB
ajlm-823	58	12	for	for	ADP
ajlm-823	58	13	alloantibodies	alloantibody	NOUN
ajlm-823	58	14	,	,	PUNCT
ajlm-823	58	15	bugando	bugando	ADJ
ajlm-823	58	16	medical	medical	ADJ
ajlm-823	58	17	centre	centre	NOUN
ajlm-823	58	18	,	,	PUNCT
ajlm-823	58	19	may	may	PROPN
ajlm-823	58	20	2017	2017	NUM
ajlm-823	58	21	–	–	PUNCT
ajlm-823	58	22	june	june	PROPN
ajlm-823	58	23	2017.†	2017.†	NUM
ajlm-823	58	24	autoantibody	autoantibody	ADJ
ajlm-823	58	25	detection	detection	NOUN
ajlm-823	58	26	–	–	PUNCT
ajlm-823	58	27	direct	direct	ADJ
ajlm-823	58	28	antiglobulin	antiglobulin	NOUN
ajlm-823	58	29	test	test	NOUN
ajlm-823	58	30	to	to	PART
ajlm-823	58	31	rule	rule	VERB
ajlm-823	58	32	out	out	ADP
ajlm-823	58	33	autoantibodies	autoantibody	NOUN
ajlm-823	58	34	,	,	PUNCT
ajlm-823	58	35	which	which	PRON
ajlm-823	58	36	were	be	AUX
ajlm-823	58	37	not	not	PART
ajlm-823	58	38	part	part	NOUN
ajlm-823	58	39	of	of	ADP
ajlm-823	58	40	the	the	DET
ajlm-823	58	41	study	study	NOUN
ajlm-823	58	42	but	but	CCONJ
ajlm-823	58	43	can	can	AUX
ajlm-823	58	44	affect	affect	VERB
ajlm-823	58	45	test	test	NOUN
ajlm-823	58	46	results	result	NOUN
ajlm-823	58	47	,	,	PUNCT
ajlm-823	58	48	a	a	DET
ajlm-823	58	49	direct	direct	ADJ
ajlm-823	58	50	antiglobulin	antiglobulin	NOUN
ajlm-823	58	51	test	test	NOUN
ajlm-823	58	52	was	be	AUX
ajlm-823	58	53	done	do	VERB
ajlm-823	58	54	.	.	PUNCT
ajlm-823	59	1	briefly	briefly	ADV
ajlm-823	59	2	,	,	PUNCT
ajlm-823	59	3	the	the	DET
ajlm-823	59	4	patient	patient	NOUN
ajlm-823	59	5	’s	’s	PART
ajlm-823	59	6	red	red	ADJ
ajlm-823	59	7	blood	blood	NOUN
ajlm-823	59	8	cells	cell	NOUN
ajlm-823	59	9	were	be	AUX
ajlm-823	59	10	washed	wash	VERB
ajlm-823	59	11	three	three	NUM
ajlm-823	59	12	times	time	NOUN
ajlm-823	59	13	with	with	ADP
ajlm-823	59	14	normal	normal	ADJ
ajlm-823	59	15	saline	saline	NOUN
ajlm-823	59	16	.	.	PUNCT
ajlm-823	60	1	two	two	NUM
ajlm-823	60	2	drops	drop	NOUN
ajlm-823	60	3	of	of	ADP
ajlm-823	60	4	anti	anti	ADJ
ajlm-823	60	5	-	-	ADJ
ajlm-823	60	6	human	human	ADJ
ajlm-823	60	7	globulin	globulin	NOUN
ajlm-823	60	8	(	(	PUNCT
ajlm-823	60	9	coombs	coombs	PROPN
ajlm-823	60	10	reagent	reagent	NOUN
ajlm-823	60	11	)	)	PUNCT
ajlm-823	60	12	was	be	AUX
ajlm-823	60	13	added	add	VERB
ajlm-823	60	14	to	to	ADP
ajlm-823	60	15	the	the	DET
ajlm-823	60	16	washed	wash	VERB
ajlm-823	60	17	cells	cell	NOUN
ajlm-823	60	18	,	,	PUNCT
ajlm-823	60	19	mixed	mixed	ADJ
ajlm-823	60	20	and	and	CCONJ
ajlm-823	60	21	centrifuged	centrifuge	VERB
ajlm-823	60	22	at	at	ADP
ajlm-823	60	23	1500	1500	NUM
ajlm-823	60	24	revolutions	revolution	NOUN
ajlm-823	60	25	per	per	ADP
ajlm-823	60	26	minute	minute	NOUN
ajlm-823	60	27	for	for	ADP
ajlm-823	60	28	3	3	NUM
ajlm-823	60	29	min	min	NOUN
ajlm-823	60	30	.	.	PUNCT
ajlm-823	61	1	the	the	DET
ajlm-823	61	2	centrifuged	centrifuged	ADJ
ajlm-823	61	3	mixture	mixture	NOUN
ajlm-823	61	4	of	of	ADP
ajlm-823	61	5	patient	patient	ADJ
ajlm-823	61	6	rbc	rbc	PROPN
ajlm-823	61	7	and	and	CCONJ
ajlm-823	61	8	anti	anti	ADJ
ajlm-823	61	9	-	-	ADJ
ajlm-823	61	10	human	human	ADJ
ajlm-823	61	11	globulin	globulin	NOUN
ajlm-823	61	12	was	be	AUX
ajlm-823	61	13	read	read	VERB
ajlm-823	61	14	microscopically	microscopically	ADV
ajlm-823	61	15	for	for	ADP
ajlm-823	61	16	agglutination	agglutination	NOUN
ajlm-823	61	17	.	.	PUNCT
ajlm-823	62	1	tubes	tube	NOUN
ajlm-823	62	2	with	with	ADP
ajlm-823	62	3	agglutination	agglutination	NOUN
ajlm-823	62	4	were	be	AUX
ajlm-823	62	5	considered	consider	VERB
ajlm-823	62	6	‘	'	PUNCT
ajlm-823	62	7	positive	positive	ADJ
ajlm-823	62	8	’	'	PUNCT
ajlm-823	62	9	for	for	ADP
ajlm-823	62	10	autoantibodies	autoantibody	NOUN
ajlm-823	62	11	,	,	PUNCT
ajlm-823	62	12	whereas	whereas	SCONJ
ajlm-823	62	13	tubes	tube	NOUN
ajlm-823	62	14	with	with	ADP
ajlm-823	62	15	no	no	DET
ajlm-823	62	16	agglutination	agglutination	NOUN
ajlm-823	62	17	were	be	AUX
ajlm-823	62	18	considered	consider	VERB
ajlm-823	62	19	‘	'	PUNCT
ajlm-823	62	20	negative	negative	ADJ
ajlm-823	62	21	’	'	PUNCT
ajlm-823	62	22	for	for	ADP
ajlm-823	62	23	autoantibodies	autoantibody	NOUN
ajlm-823	62	24	.	.	PUNCT
ajlm-823	63	1	to	to	PART
ajlm-823	63	2	rule	rule	VERB
ajlm-823	63	3	out	out	ADP
ajlm-823	63	4	anti	anti	ADJ
ajlm-823	63	5	-	-	ADJ
ajlm-823	63	6	human	human	ADJ
ajlm-823	63	7	globulin	globulin	NOUN
ajlm-823	63	8	non	non	NOUN
ajlm-823	63	9	-	-	NOUN
ajlm-823	63	10	reactivity	reactivity	NOUN
ajlm-823	63	11	and	and	CCONJ
ajlm-823	63	12	validate	validate	VERB
ajlm-823	63	13	negative	negative	ADJ
ajlm-823	63	14	results	result	NOUN
ajlm-823	63	15	(	(	PUNCT
ajlm-823	63	16	tubes	tube	NOUN
ajlm-823	63	17	without	without	ADP
ajlm-823	63	18	agglutination	agglutination	NOUN
ajlm-823	63	19	)	)	PUNCT
ajlm-823	63	20	,	,	PUNCT
ajlm-823	63	21	pre	pre	ADJ
ajlm-823	63	22	-	-	ADJ
ajlm-823	63	23	sensitised	sensitised	ADJ
ajlm-823	63	24	commercial	commercial	ADJ
ajlm-823	63	25	rbcs	rbc	NOUN
ajlm-823	63	26	(	(	PUNCT
ajlm-823	63	27	lorne	lorne	PROPN
ajlm-823	63	28	laboratories	laboratory	NOUN
ajlm-823	63	29	;	;	PUNCT
ajlm-823	63	30	reading	reading	NOUN
ajlm-823	63	31	,	,	PUNCT
ajlm-823	63	32	berkshire	berkshire	NOUN
ajlm-823	63	33	,	,	PUNCT
ajlm-823	63	34	united	united	ADJ
ajlm-823	63	35	kingdom	kingdom	PROPN
ajlm-823	63	36	)	)	PUNCT
ajlm-823	63	37	coated	coat	VERB
ajlm-823	63	38	with	with	ADP
ajlm-823	63	39	short	short	ADJ
ajlm-823	63	40	-	-	PUNCT
ajlm-823	63	41	armed	armed	ADJ
ajlm-823	63	42	antibodies	antibody	NOUN
ajlm-823	63	43	were	be	AUX
ajlm-823	63	44	added	add	VERB
ajlm-823	63	45	.	.	PUNCT
ajlm-823	64	1	if	if	SCONJ
ajlm-823	64	2	agglutination	agglutination	NOUN
ajlm-823	64	3	was	be	AUX
ajlm-823	64	4	observed	observe	VERB
ajlm-823	64	5	,	,	PUNCT
ajlm-823	64	6	which	which	PRON
ajlm-823	64	7	was	be	AUX
ajlm-823	64	8	expected	expect	VERB
ajlm-823	64	9	,	,	PUNCT
ajlm-823	64	10	then	then	ADV
ajlm-823	64	11	anti	anti	ADJ
ajlm-823	64	12	-	-	ADJ
ajlm-823	64	13	human	human	ADJ
ajlm-823	64	14	globulin	globulin	NOUN
ajlm-823	64	15	was	be	AUX
ajlm-823	64	16	reactive	reactive	ADJ
ajlm-823	64	17	and	and	CCONJ
ajlm-823	64	18	the	the	DET
ajlm-823	64	19	patient	patient	NOUN
ajlm-823	64	20	’s	’s	PART
ajlm-823	64	21	result	result	NOUN
ajlm-823	64	22	was	be	AUX
ajlm-823	64	23	considered	consider	VERB
ajlm-823	64	24	valid	valid	ADJ
ajlm-823	64	25	.	.	PUNCT
ajlm-823	65	1	data	datum	NOUN
ajlm-823	65	2	management	management	NOUN
ajlm-823	65	3	and	and	CCONJ
ajlm-823	65	4	statistical	statistical	ADJ
ajlm-823	65	5	analysis	analysis	NOUN
ajlm-823	65	6	after	after	ADP
ajlm-823	65	7	cross	cross	ADJ
ajlm-823	65	8	-	-	ADJ
ajlm-823	65	9	checking	checking	ADJ
ajlm-823	65	10	,	,	PUNCT
ajlm-823	65	11	data	datum	NOUN
ajlm-823	65	12	were	be	AUX
ajlm-823	65	13	transferred	transfer	VERB
ajlm-823	65	14	directly	directly	ADV
ajlm-823	65	15	to	to	ADP
ajlm-823	65	16	statistical	statistical	ADJ
ajlm-823	65	17	package	package	NOUN
ajlm-823	65	18	for	for	ADP
ajlm-823	65	19	social	social	ADJ
ajlm-823	65	20	sciences	science	NOUN
ajlm-823	65	21	software	software	NOUN
ajlm-823	65	22	(	(	PUNCT
ajlm-823	65	23	international	international	ADJ
ajlm-823	65	24	business	business	NOUN
ajlm-823	65	25	machines	machine	NOUN
ajlm-823	65	26	corporation	corporation	PROPN
ajlm-823	65	27	,	,	PUNCT
ajlm-823	65	28	chicago	chicago	PROPN
ajlm-823	65	29	,	,	PUNCT
ajlm-823	65	30	illinois	illinois	PROPN
ajlm-823	65	31	,	,	PUNCT
ajlm-823	65	32	united	united	PROPN
ajlm-823	65	33	states	states	PROPN
ajlm-823	65	34	)	)	PUNCT
ajlm-823	65	35	version	version	NOUN
ajlm-823	65	36	20	20	NUM
ajlm-823	65	37	and	and	CCONJ
ajlm-823	65	38	analysed	analyse	VERB
ajlm-823	65	39	.	.	PUNCT
ajlm-823	66	1	continuous	continuous	ADJ
ajlm-823	66	2	data	datum	NOUN
ajlm-823	66	3	were	be	AUX
ajlm-823	66	4	presented	present	VERB
ajlm-823	66	5	using	use	VERB
ajlm-823	66	6	medians	median	NOUN
ajlm-823	66	7	and	and	CCONJ
ajlm-823	66	8	interquartile	interquartile	ADJ
ajlm-823	66	9	range	range	NOUN
ajlm-823	66	10	,	,	PUNCT
ajlm-823	66	11	and	and	CCONJ
ajlm-823	66	12	the	the	DET
ajlm-823	66	13	chi	chi	NOUN
ajlm-823	66	14	-	-	PUNCT
ajlm-823	66	15	square	square	PROPN
ajlm-823	66	16	was	be	AUX
ajlm-823	66	17	used	use	VERB
ajlm-823	66	18	to	to	PART
ajlm-823	66	19	test	test	VERB
ajlm-823	66	20	associations	association	NOUN
ajlm-823	66	21	for	for	ADP
ajlm-823	66	22	categories	category	NOUN
ajlm-823	66	23	available	available	ADJ
ajlm-823	66	24	.	.	PUNCT
ajlm-823	67	1	p	p	X
ajlm-823	67	2	<	<	X
ajlm-823	67	3	0.05	0.05	NUM
ajlm-823	67	4	was	be	AUX
ajlm-823	67	5	considered	consider	VERB
ajlm-823	67	6	statistically	statistically	ADV
ajlm-823	67	7	significant	significant	ADJ
ajlm-823	67	8	.	.	PUNCT
ajlm-823	68	1	results	result	VERB
ajlm-823	68	2	the	the	DET
ajlm-823	68	3	median	median	ADJ
ajlm-823	68	4	age	age	NOUN
ajlm-823	68	5	of	of	ADP
ajlm-823	68	6	the	the	DET
ajlm-823	68	7	study	study	NOUN
ajlm-823	68	8	participants	participant	NOUN
ajlm-823	68	9	was	be	AUX
ajlm-823	68	10	4.5	4.5	NUM
ajlm-823	68	11	years	year	NOUN
ajlm-823	68	12	(	(	PUNCT
ajlm-823	68	13	range	range	NOUN
ajlm-823	68	14	:	:	PUNCT
ajlm-823	68	15	0–26	0–26	NOUN
ajlm-823	68	16	years	year	NOUN
ajlm-823	68	17	)	)	PUNCT
ajlm-823	68	18	(	(	PUNCT
ajlm-823	68	19	table	table	NOUN
ajlm-823	68	20	2	2	NUM
ajlm-823	68	21	)	)	PUNCT
ajlm-823	68	22	.	.	PUNCT
ajlm-823	69	1	of	of	ADP
ajlm-823	69	2	the	the	DET
ajlm-823	69	3	200	200	NUM
ajlm-823	69	4	patients	patient	NOUN
ajlm-823	69	5	enrolled	enrol	VERB
ajlm-823	69	6	,	,	PUNCT
ajlm-823	69	7	17	17	NUM
ajlm-823	69	8	patients	patient	NOUN
ajlm-823	69	9	were	be	AUX
ajlm-823	69	10	positive	positive	ADJ
ajlm-823	69	11	for	for	ADP
ajlm-823	69	12	alloantibodies	alloantibody	NOUN
ajlm-823	69	13	.	.	PUNCT
ajlm-823	70	1	no	no	DET
ajlm-823	70	2	autoantibodies	autoantibody	NOUN
ajlm-823	70	3	were	be	AUX
ajlm-823	70	4	detected	detect	VERB
ajlm-823	70	5	in	in	ADP
ajlm-823	70	6	any	any	DET
ajlm-823	70	7	patient	patient	NOUN
ajlm-823	70	8	;	;	PUNCT
ajlm-823	70	9	all	all	DET
ajlm-823	70	10	direct	direct	ADJ
ajlm-823	70	11	antiglobulin	antiglobulin	NOUN
ajlm-823	70	12	tests	test	NOUN
ajlm-823	70	13	were	be	AUX
ajlm-823	70	14	negative	negative	ADJ
ajlm-823	70	15	.	.	PUNCT
ajlm-823	71	1	one	one	NUM
ajlm-823	71	2	patient	patient	NOUN
ajlm-823	71	3	developed	develop	VERB
ajlm-823	71	4	immunoglobulin	immunoglobulin	NOUN
ajlm-823	71	5	m	m	PROPN
ajlm-823	71	6	cold	cold	ADJ
ajlm-823	71	7	antibodies	antibody	NOUN
ajlm-823	71	8	and	and	CCONJ
ajlm-823	71	9	was	be	AUX
ajlm-823	71	10	excluded	exclude	VERB
ajlm-823	71	11	from	from	ADP
ajlm-823	71	12	downstream	downstream	ADJ
ajlm-823	71	13	analysis	analysis	NOUN
ajlm-823	71	14	,	,	PUNCT
ajlm-823	71	15	but	but	CCONJ
ajlm-823	71	16	did	do	AUX
ajlm-823	71	17	not	not	PART
ajlm-823	71	18	experience	experience	VERB
ajlm-823	71	19	the	the	DET
ajlm-823	71	20	consequent	consequent	ADJ
ajlm-823	71	21	nuisance	nuisance	ADJ
ajlm-823	71	22	hemolysis	hemolysis	NOUN
ajlm-823	71	23	.	.	PUNCT
ajlm-823	72	1	table	table	NOUN
ajlm-823	72	2	2	2	NUM
ajlm-823	72	3	:	:	PUNCT
ajlm-823	72	4	 	 	SPACE
ajlm-823	72	5	demographic	demographic	ADJ
ajlm-823	72	6	characteristics	characteristic	NOUN
ajlm-823	72	7	of	of	ADP
ajlm-823	72	8	sickle	sickle	NOUN
ajlm-823	72	9	cell	cell	NOUN
ajlm-823	72	10	disease	disease	NOUN
ajlm-823	72	11	patients	patient	NOUN
ajlm-823	72	12	with	with	ADP
ajlm-823	72	13	multiple	multiple	ADJ
ajlm-823	72	14	transfusions	transfusion	NOUN
ajlm-823	72	15	at	at	ADP
ajlm-823	72	16	bugando	bugando	ADJ
ajlm-823	72	17	medical	medical	ADJ
ajlm-823	72	18	centre	centre	NOUN
ajlm-823	72	19	,	,	PUNCT
ajlm-823	72	20	may	may	PROPN
ajlm-823	72	21	2017	2017	NUM
ajlm-823	72	22	–	–	PUNCT
ajlm-823	72	23	july	july	PROPN
ajlm-823	72	24	2017.†	2017.†	PROPN
ajlm-823	72	25	a	a	DET
ajlm-823	72	26	total	total	NOUN
ajlm-823	72	27	of	of	ADP
ajlm-823	72	28	17	17	NUM
ajlm-823	72	29	(	(	PUNCT
ajlm-823	72	30	8.5	8.5	NUM
ajlm-823	72	31	%	%	NOUN
ajlm-823	72	32	)	)	PUNCT
ajlm-823	73	1	patients	patient	NOUN
ajlm-823	73	2	developed	develop	VERB
ajlm-823	73	3	23	23	NUM
ajlm-823	73	4	warm	warm	ADJ
ajlm-823	73	5	alloantibodies	alloantibody	NOUN
ajlm-823	73	6	and	and	CCONJ
ajlm-823	73	7	183	183	NUM
ajlm-823	73	8	(	(	PUNCT
ajlm-823	73	9	91.5	91.5	NUM
ajlm-823	73	10	%	%	NOUN
ajlm-823	73	11	)	)	PUNCT
ajlm-823	73	12	tested	test	VERB
ajlm-823	73	13	negative	negative	ADJ
ajlm-823	73	14	for	for	ADP
ajlm-823	73	15	warm	warm	ADJ
ajlm-823	73	16	alloantibodies	alloantibody	NOUN
ajlm-823	73	17	(	(	PUNCT
ajlm-823	73	18	table	table	NOUN
ajlm-823	73	19	3	3	NUM
ajlm-823	73	20	)	)	PUNCT
ajlm-823	73	21	.	.	PUNCT
ajlm-823	74	1	of	of	ADP
ajlm-823	74	2	the	the	DET
ajlm-823	74	3	17	17	NUM
ajlm-823	74	4	patients	patient	NOUN
ajlm-823	74	5	that	that	PRON
ajlm-823	74	6	developed	develop	VERB
ajlm-823	74	7	warm	warm	ADJ
ajlm-823	74	8	alloantibodies	alloantibody	NOUN
ajlm-823	74	9	,	,	PUNCT
ajlm-823	74	10	11	11	NUM
ajlm-823	74	11	had	have	VERB
ajlm-823	74	12	single	single	ADJ
ajlm-823	74	13	alloantibodies	alloantibody	NOUN
ajlm-823	74	14	and	and	CCONJ
ajlm-823	74	15	six	six	NUM
ajlm-823	74	16	had	have	VERB
ajlm-823	74	17	double	double	ADJ
ajlm-823	74	18	alloantibodies	alloantibody	NOUN
ajlm-823	74	19	.	.	PUNCT
ajlm-823	75	1	of	of	ADP
ajlm-823	75	2	the	the	DET
ajlm-823	75	3	23	23	NUM
ajlm-823	75	4	identified	identify	VERB
ajlm-823	75	5	alloantibodies	alloantibody	NOUN
ajlm-823	75	6	,	,	PUNCT
ajlm-823	75	7	87	87	NUM
ajlm-823	75	8	%	%	NOUN
ajlm-823	75	9	(	(	PUNCT
ajlm-823	75	10	20/23	20/23	NUM
ajlm-823	75	11	)	)	PUNCT
ajlm-823	75	12	showed	show	VERB
ajlm-823	75	13	mild	mild	ADJ
ajlm-823	75	14	agglutination	agglutination	NOUN
ajlm-823	75	15	,	,	PUNCT
ajlm-823	75	16	and	and	CCONJ
ajlm-823	75	17	13	13	NUM
ajlm-823	75	18	%	%	NOUN
ajlm-823	75	19	(	(	PUNCT
ajlm-823	75	20	3/20	3/20	NUM
ajlm-823	75	21	)	)	PUNCT
ajlm-823	75	22	showed	show	VERB
ajlm-823	75	23	strong	strong	ADJ
ajlm-823	75	24	agglutination	agglutination	NOUN
ajlm-823	75	25	.	.	PUNCT
ajlm-823	76	1	among	among	ADP
ajlm-823	76	2	the	the	DET
ajlm-823	76	3	alloimmunised	alloimmunise	VERB
ajlm-823	76	4	patients	patient	NOUN
ajlm-823	76	5	,	,	PUNCT
ajlm-823	76	6	the	the	DET
ajlm-823	76	7	number	number	NOUN
ajlm-823	76	8	of	of	ADP
ajlm-823	76	9	transfusions	transfusion	NOUN
ajlm-823	76	10	ranged	range	VERB
ajlm-823	76	11	from	from	ADP
ajlm-823	76	12	3	3	NUM
ajlm-823	76	13	units	unit	NOUN
ajlm-823	76	14	to	to	ADP
ajlm-823	76	15	6	6	NUM
ajlm-823	76	16	units	unit	NOUN
ajlm-823	76	17	within	within	ADP
ajlm-823	76	18	the	the	DET
ajlm-823	76	19	previous	previous	ADJ
ajlm-823	76	20	year	year	NOUN
ajlm-823	76	21	.	.	PUNCT
ajlm-823	77	1	there	there	PRON
ajlm-823	77	2	was	be	VERB
ajlm-823	77	3	no	no	DET
ajlm-823	77	4	significant	significant	ADJ
ajlm-823	77	5	statistical	statistical	ADJ
ajlm-823	77	6	association	association	NOUN
ajlm-823	77	7	between	between	ADP
ajlm-823	77	8	the	the	DET
ajlm-823	77	9	number	number	NOUN
ajlm-823	77	10	of	of	ADP
ajlm-823	77	11	transfusions	transfusion	NOUN
ajlm-823	77	12	and	and	CCONJ
ajlm-823	77	13	the	the	DET
ajlm-823	77	14	risk	risk	NOUN
ajlm-823	77	15	of	of	ADP
ajlm-823	77	16	alloimmunisation	alloimmunisation	NOUN
ajlm-823	77	17	[	[	X
ajlm-823	77	18	p	p	X
ajlm-823	77	19	=	=	NOUN
ajlm-823	77	20	0.07	0.07	NUM
ajlm-823	77	21	]	]	PUNCT
ajlm-823	77	22	.	.	PUNCT
ajlm-823	78	1	the	the	DET
ajlm-823	78	2	median	median	ADJ
ajlm-823	78	3	number	number	NOUN
ajlm-823	78	4	of	of	ADP
ajlm-823	78	5	transfusions	transfusion	NOUN
ajlm-823	78	6	for	for	ADP
ajlm-823	78	7	patients	patient	NOUN
ajlm-823	78	8	without	without	ADP
ajlm-823	78	9	alloantibodies	alloantibody	NOUN
ajlm-823	78	10	was	be	AUX
ajlm-823	78	11	2	2	NUM
ajlm-823	78	12	(	(	PUNCT
ajlm-823	78	13	median	median	NOUN
ajlm-823	78	14	:	:	PUNCT
ajlm-823	78	15	1.0	1.0	NUM
ajlm-823	78	16	)	)	PUNCT
ajlm-823	78	17	units	unit	NOUN
ajlm-823	78	18	of	of	ADP
ajlm-823	78	19	blood	blood	NOUN
ajlm-823	78	20	.	.	PUNCT
ajlm-823	79	1	all	all	DET
ajlm-823	79	2	183	183	NUM
ajlm-823	79	3	patients	patient	NOUN
ajlm-823	79	4	who	who	PRON
ajlm-823	79	5	were	be	AUX
ajlm-823	79	6	negative	negative	ADJ
ajlm-823	79	7	for	for	ADP
ajlm-823	79	8	warm	warm	ADJ
ajlm-823	79	9	alloantibodies	alloantibody	NOUN
ajlm-823	79	10	received	receive	VERB
ajlm-823	79	11	≤	≤	ADJ
ajlm-823	79	12	2	2	NUM
ajlm-823	79	13	transfusions	transfusion	NOUN
ajlm-823	79	14	.	.	PUNCT
ajlm-823	80	1	table	table	NOUN
ajlm-823	80	2	3	3	NUM
ajlm-823	80	3	:	:	PUNCT
ajlm-823	80	4	 	 	SPACE
ajlm-823	80	5	demographic	demographic	ADJ
ajlm-823	80	6	characteristics	characteristic	NOUN
ajlm-823	80	7	of	of	ADP
ajlm-823	80	8	sickle	sickle	NOUN
ajlm-823	80	9	cell	cell	NOUN
ajlm-823	80	10	patients	patient	NOUN
ajlm-823	80	11	having	have	VERB
ajlm-823	80	12	warm	warm	ADJ
ajlm-823	80	13	alloantibodies	alloantibody	NOUN
ajlm-823	80	14	at	at	ADP
ajlm-823	80	15	bugando	bugando	ADJ
ajlm-823	80	16	medical	medical	ADJ
ajlm-823	80	17	centre	centre	NOUN
ajlm-823	80	18	,	,	PUNCT
ajlm-823	80	19	may	may	PROPN
ajlm-823	80	20	2017	2017	NUM
ajlm-823	80	21	–	–	PUNCT
ajlm-823	80	22	july	july	PROPN
ajlm-823	80	23	2017	2017	NUM
ajlm-823	80	24	.	.	PUNCT
ajlm-823	81	1	of	of	ADP
ajlm-823	81	2	the	the	DET
ajlm-823	81	3	23	23	NUM
ajlm-823	81	4	identified	identify	VERB
ajlm-823	81	5	alloantibodies	alloantibody	NOUN
ajlm-823	81	6	,	,	PUNCT
ajlm-823	81	7	12	12	NUM
ajlm-823	81	8	were	be	AUX
ajlm-823	81	9	of	of	ADP
ajlm-823	81	10	the	the	DET
ajlm-823	81	11	rhesus	rhesus	NOUN
ajlm-823	81	12	group	group	NOUN
ajlm-823	81	13	(	(	PUNCT
ajlm-823	81	14	anti	anti	ADJ
ajlm-823	81	15	-	-	ADJ
ajlm-823	81	16	e	e	ADJ
ajlm-823	81	17	[	[	X
ajlm-823	81	18	2	2	NUM
ajlm-823	81	19	]	]	PUNCT
ajlm-823	81	20	,	,	PUNCT
ajlm-823	81	21	anti	anti	ADJ
ajlm-823	81	22	-	-	NOUN
ajlm-823	81	23	c	c	ADJ
ajlm-823	81	24	[	[	X
ajlm-823	81	25	6	6	NUM
ajlm-823	81	26	]	]	PUNCT
ajlm-823	81	27	,	,	PUNCT
ajlm-823	81	28	anti	anti	ADJ
ajlm-823	81	29	-	-	NOUN
ajlm-823	81	30	c	c	ADJ
ajlm-823	81	31	[	[	X
ajlm-823	81	32	3	3	NUM
ajlm-823	81	33	]	]	PUNCT
ajlm-823	81	34	,	,	PUNCT
ajlm-823	81	35	anti	anti	ADJ
ajlm-823	81	36	-	-	ADJ
ajlm-823	81	37	e	e	ADJ
ajlm-823	81	38	[	[	X
ajlm-823	81	39	1	1	NUM
ajlm-823	81	40	]	]	NUM
ajlm-823	81	41	)	)	PUNCT
ajlm-823	81	42	,	,	PUNCT
ajlm-823	81	43	6	6	NUM
ajlm-823	81	44	were	be	AUX
ajlm-823	81	45	of	of	ADP
ajlm-823	81	46	the	the	DET
ajlm-823	81	47	kell	kell	PROPN
ajlm-823	81	48	group	group	PROPN
ajlm-823	81	49	(	(	PUNCT
ajlm-823	81	50	anti	anti	ADJ
ajlm-823	81	51	-	-	ADJ
ajlm-823	81	52	k	k	NOUN
ajlm-823	81	53	)	)	PUNCT
ajlm-823	81	54	,	,	PUNCT
ajlm-823	81	55	2	2	NUM
ajlm-823	81	56	were	be	AUX
ajlm-823	81	57	of	of	ADP
ajlm-823	81	58	the	the	DET
ajlm-823	81	59	mns	mns	PROPN
ajlm-823	81	60	group	group	NOUN
ajlm-823	81	61	(	(	PUNCT
ajlm-823	81	62	anti	anti	ADJ
ajlm-823	81	63	-	-	ADJ
ajlm-823	81	64	m	m	NOUN
ajlm-823	81	65	)	)	PUNCT
ajlm-823	81	66	,	,	PUNCT
ajlm-823	81	67	1	1	NUM
ajlm-823	81	68	was	be	AUX
ajlm-823	81	69	of	of	ADP
ajlm-823	81	70	the	the	DET
ajlm-823	81	71	kidd	kidd	PROPN
ajlm-823	81	72	group	group	PROPN
ajlm-823	81	73	(	(	PUNCT
ajlm-823	81	74	jka	jka	PROPN
ajlm-823	81	75	)	)	PUNCT
ajlm-823	81	76	,	,	PUNCT
ajlm-823	81	77	1	1	NUM
ajlm-823	81	78	was	be	AUX
ajlm-823	81	79	of	of	ADP
ajlm-823	81	80	the	the	DET
ajlm-823	81	81	duffy	duffy	PROPN
ajlm-823	81	82	group	group	PROPN
ajlm-823	81	83	(	(	PUNCT
ajlm-823	81	84	fya	fya	PROPN
ajlm-823	81	85	)	)	PUNCT
ajlm-823	81	86	and	and	CCONJ
ajlm-823	81	87	1	1	NUM
ajlm-823	81	88	was	be	AUX
ajlm-823	81	89	of	of	ADP
ajlm-823	81	90	the	the	DET
ajlm-823	81	91	lewis	lewis	PROPN
ajlm-823	81	92	group	group	PROPN
ajlm-823	81	93	(	(	PUNCT
ajlm-823	81	94	lea	lea	PROPN
ajlm-823	81	95	)	)	PUNCT
ajlm-823	81	96	(	(	PUNCT
ajlm-823	81	97	table	table	NOUN
ajlm-823	81	98	4	4	NUM
ajlm-823	81	99	)	)	PUNCT
ajlm-823	81	100	.	.	PUNCT
ajlm-823	82	1	table	table	NOUN
ajlm-823	82	2	4	4	NUM
ajlm-823	82	3	:	:	PUNCT
ajlm-823	82	4	 	 	SPACE
ajlm-823	82	5	warm	warm	ADJ
ajlm-823	82	6	alloantibodies	alloantibody	NOUN
ajlm-823	82	7	in	in	ADP
ajlm-823	82	8	sickle	sickle	NOUN
ajlm-823	82	9	cell	cell	NOUN
ajlm-823	82	10	patients	patient	NOUN
ajlm-823	82	11	with	with	ADP
ajlm-823	82	12	multiple	multiple	ADJ
ajlm-823	82	13	blood	blood	NOUN
ajlm-823	82	14	transfusions	transfusion	NOUN
ajlm-823	82	15	who	who	PRON
ajlm-823	82	16	tested	test	VERB
ajlm-823	82	17	positive	positive	ADJ
ajlm-823	82	18	for	for	ADP
ajlm-823	82	19	alloantibody	alloantibody	ADJ
ajlm-823	82	20	screening	screening	NOUN
ajlm-823	82	21	,	,	PUNCT
ajlm-823	82	22	bugando	bugando	ADV
ajlm-823	82	23	medical	medical	ADJ
ajlm-823	82	24	centre	centre	NOUN
ajlm-823	82	25	,	,	PUNCT
ajlm-823	82	26	may	may	PROPN
ajlm-823	82	27	2017	2017	NUM
ajlm-823	82	28	–	–	PUNCT
ajlm-823	82	29	june	june	PROPN
ajlm-823	82	30	2017	2017	NUM
ajlm-823	82	31	.	.	PUNCT
ajlm-823	83	1	discussion	discussion	NOUN
ajlm-823	83	2	the	the	DET
ajlm-823	83	3	alloimmunisation	alloimmunisation	NOUN
ajlm-823	83	4	rate	rate	NOUN
ajlm-823	83	5	in	in	ADP
ajlm-823	83	6	the	the	DET
ajlm-823	83	7	current	current	ADJ
ajlm-823	83	8	study	study	NOUN
ajlm-823	83	9	is	be	AUX
ajlm-823	83	10	higher	high	ADJ
ajlm-823	83	11	than	than	ADP
ajlm-823	83	12	the	the	DET
ajlm-823	83	13	6.1	6.1	NUM
ajlm-823	83	14	%	%	NOUN
ajlm-823	83	15	alloimmunisation	alloimmunisation	NOUN
ajlm-823	83	16	rate	rate	NOUN
ajlm-823	83	17	reported	report	VERB
ajlm-823	83	18	by	by	ADP
ajlm-823	83	19	natukunda	natukunda	PROPN
ajlm-823	83	20	et	et	PROPN
ajlm-823	83	21	al	al	PROPN
ajlm-823	83	22	.	.	PROPN
ajlm-823	84	1	in	in	ADP
ajlm-823	84	2	mulago	mulago	PROPN
ajlm-823	84	3	kampala	kampala	PROPN
ajlm-823	84	4	uganda	uganda	PROPN
ajlm-823	84	5	and	and	CCONJ
ajlm-823	84	6	the	the	DET
ajlm-823	84	7	4.1	4.1	NUM
ajlm-823	84	8	%	%	NOUN
ajlm-823	84	9	rate	rate	NOUN
ajlm-823	84	10	reported	report	VERB
ajlm-823	84	11	by	by	ADP
ajlm-823	84	12	meda	meda	PROPN
ajlm-823	84	13	et	et	PROPN
ajlm-823	84	14	al	al	PROPN
ajlm-823	84	15	.	.	PROPN
ajlm-823	85	1	in	in	ADP
ajlm-823	85	2	muhimbili	muhimbili	PROPN
ajlm-823	85	3	dar	dar	PROPN
ajlm-823	85	4	es	es	PROPN
ajlm-823	85	5	salaam	salaam	PROPN
ajlm-823	85	6	,	,	PUNCT
ajlm-823	85	7	tanzania.9,10	tanzania.9,10	NOUN
ajlm-823	85	8	the	the	DET
ajlm-823	85	9	differences	difference	NOUN
ajlm-823	85	10	in	in	ADP
ajlm-823	85	11	these	these	DET
ajlm-823	85	12	rates	rate	NOUN
ajlm-823	85	13	could	could	AUX
ajlm-823	85	14	be	be	AUX
ajlm-823	85	15	attributed	attribute	VERB
ajlm-823	85	16	to	to	ADP
ajlm-823	85	17	differences	difference	NOUN
ajlm-823	85	18	in	in	ADP
ajlm-823	85	19	the	the	DET
ajlm-823	85	20	median	median	ADJ
ajlm-823	85	21	number	number	NOUN
ajlm-823	85	22	of	of	ADP
ajlm-823	85	23	blood	blood	NOUN
ajlm-823	85	24	transfusions	transfusion	NOUN
ajlm-823	85	25	,	,	PUNCT
ajlm-823	85	26	which	which	PRON
ajlm-823	85	27	was	be	AUX
ajlm-823	85	28	lower	low	ADJ
ajlm-823	85	29	(	(	PUNCT
ajlm-823	85	30	mean	mean	ADJ
ajlm-823	85	31	,	,	PUNCT
ajlm-823	85	32	2(0	2(0	NUM
ajlm-823	85	33	)	)	PUNCT
ajlm-823	85	34	units	unit	NOUN
ajlm-823	85	35	)	)	PUNCT
ajlm-823	85	36	in	in	ADP
ajlm-823	85	37	the	the	DET
ajlm-823	85	38	other	other	ADJ
ajlm-823	85	39	two	two	NUM
ajlm-823	85	40	studies	study	NOUN
ajlm-823	85	41	,	,	PUNCT
ajlm-823	85	42	whereas	whereas	SCONJ
ajlm-823	85	43	the	the	DET
ajlm-823	85	44	mean	mean	ADJ
ajlm-823	85	45	number	number	NOUN
ajlm-823	85	46	of	of	ADP
ajlm-823	85	47	transfusions	transfusion	NOUN
ajlm-823	85	48	at	at	ADP
ajlm-823	85	49	bmc	bmc	PROPN
ajlm-823	85	50	was	be	AUX
ajlm-823	85	51	3(1	3(1	NUM
ajlm-823	85	52	)	)	PUNCT
ajlm-823	85	53	units	unit	NOUN
ajlm-823	85	54	.	.	PUNCT
ajlm-823	86	1	the	the	DET
ajlm-823	86	2	alloimmunisation	alloimmunisation	NOUN
ajlm-823	86	3	rate	rate	NOUN
ajlm-823	86	4	of	of	ADP
ajlm-823	86	5	the	the	DET
ajlm-823	86	6	current	current	ADJ
ajlm-823	86	7	study	study	NOUN
ajlm-823	86	8	was	be	AUX
ajlm-823	86	9	comparable	comparable	ADJ
ajlm-823	86	10	to	to	ADP
ajlm-823	86	11	that	that	PRON
ajlm-823	86	12	reported	report	VERB
ajlm-823	86	13	by	by	ADP
ajlm-823	86	14	ugwe	ugwe	PROPN
ajlm-823	86	15	et	et	NOUN
ajlm-823	86	16	al.3	al.3	PROPN
ajlm-823	86	17	of	of	ADP
ajlm-823	86	18	9.3	9.3	NUM
ajlm-823	86	19	%	%	NOUN
ajlm-823	86	20	.	.	PUNCT
ajlm-823	87	1	the	the	DET
ajlm-823	87	2	study	study	NOUN
ajlm-823	87	3	included	include	VERB
ajlm-823	87	4	145	145	NUM
ajlm-823	87	5	scd	scd	NOUN
ajlm-823	87	6	patients	patient	NOUN
ajlm-823	87	7	in	in	ADP
ajlm-823	87	8	nigeria	nigeria	PROPN
ajlm-823	87	9	;	;	PUNCT
ajlm-823	87	10	blood	blood	NOUN
ajlm-823	87	11	transfusion	transfusion	NOUN
ajlm-823	87	12	was	be	AUX
ajlm-823	87	13	found	find	VERB
ajlm-823	87	14	to	to	PART
ajlm-823	87	15	be	be	AUX
ajlm-823	87	16	significantly	significantly	ADV
ajlm-823	87	17	associated	associate	VERB
ajlm-823	87	18	with	with	ADP
ajlm-823	87	19	alloimmunisation	alloimmunisation	NOUN
ajlm-823	87	20	(	(	PUNCT
ajlm-823	87	21	p	p	X
ajlm-823	87	22	=	=	X
ajlm-823	87	23	0.027	0.027	NUM
ajlm-823	87	24	where	where	SCONJ
ajlm-823	87	25	p	p	X
ajlm-823	87	26	<	<	X
ajlm-823	87	27	0.05	0.05	NUM
ajlm-823	87	28	)	)	PUNCT
ajlm-823	87	29	.	.	PUNCT
ajlm-823	88	1	as	as	ADP
ajlm-823	88	2	with	with	ADP
ajlm-823	88	3	our	our	PRON
ajlm-823	88	4	study	study	NOUN
ajlm-823	88	5	,	,	PUNCT
ajlm-823	88	6	sex	sex	NOUN
ajlm-823	88	7	was	be	AUX
ajlm-823	88	8	not	not	PART
ajlm-823	88	9	statistically	statistically	ADV
ajlm-823	88	10	significantly	significantly	ADV
ajlm-823	88	11	associated	associate	VERB
ajlm-823	88	12	with	with	ADP
ajlm-823	88	13	the	the	DET
ajlm-823	88	14	risk	risk	NOUN
ajlm-823	88	15	of	of	ADP
ajlm-823	88	16	alloimmunisation	alloimmunisation	NOUN
ajlm-823	88	17	in	in	ADP
ajlm-823	88	18	all	all	DET
ajlm-823	88	19	three	three	NUM
ajlm-823	88	20	studies	study	NOUN
ajlm-823	88	21	.	.	PUNCT
ajlm-823	89	1	as	as	ADP
ajlm-823	89	2	of	of	ADP
ajlm-823	89	3	2018	2018	NUM
ajlm-823	89	4	,	,	PUNCT
ajlm-823	89	5	tanzania	tanzania	PROPN
ajlm-823	89	6	was	be	AUX
ajlm-823	89	7	the	the	DET
ajlm-823	89	8	third	third	ADJ
ajlm-823	89	9	leading	lead	VERB
ajlm-823	89	10	country	country	NOUN
ajlm-823	89	11	in	in	ADP
ajlm-823	89	12	africa	africa	PROPN
ajlm-823	89	13	for	for	ADP
ajlm-823	89	14	sickle	sickle	NOUN
ajlm-823	89	15	cell	cell	NOUN
ajlm-823	89	16	anaemia	anaemia	NOUN
ajlm-823	89	17	after	after	ADP
ajlm-823	89	18	the	the	DET
ajlm-823	89	19	democratic	democratic	PROPN
ajlm-823	89	20	republic	republic	NOUN
ajlm-823	89	21	of	of	ADP
ajlm-823	89	22	the	the	DET
ajlm-823	89	23	congo	congo	NOUN
ajlm-823	89	24	and	and	CCONJ
ajlm-823	89	25	nigeria.11	nigeria.11	VERB
ajlm-823	89	26	the	the	DET
ajlm-823	89	27	detection	detection	NOUN
ajlm-823	89	28	of	of	ADP
ajlm-823	89	29	alloantibodies	alloantibody	NOUN
ajlm-823	89	30	of	of	ADP
ajlm-823	89	31	the	the	DET
ajlm-823	89	32	kell	kell	PROPN
ajlm-823	89	33	,	,	PUNCT
ajlm-823	89	34	mns	mns	PROPN
ajlm-823	89	35	,	,	PUNCT
ajlm-823	89	36	kidd	kidd	PROPN
ajlm-823	89	37	,	,	PUNCT
ajlm-823	89	38	duffy	duffy	PROPN
ajlm-823	89	39	and	and	CCONJ
ajlm-823	89	40	lewis	lewis	PROPN
ajlm-823	89	41	blood	blood	NOUN
ajlm-823	89	42	groups	group	NOUN
ajlm-823	89	43	is	be	AUX
ajlm-823	89	44	common12	common12	ADJ
ajlm-823	89	45	and	and	CCONJ
ajlm-823	89	46	is	be	AUX
ajlm-823	89	47	corroborated	corroborate	VERB
ajlm-823	89	48	by	by	ADP
ajlm-823	89	49	our	our	PRON
ajlm-823	89	50	study	study	NOUN
ajlm-823	89	51	as	as	ADP
ajlm-823	89	52	anti	anti	ADJ
ajlm-823	89	53	-	-	ADJ
ajlm-823	89	54	c	c	ADJ
ajlm-823	89	55	,	,	PUNCT
ajlm-823	89	56	anti	anti	ADJ
ajlm-823	89	57	-	-	ADJ
ajlm-823	89	58	c	c	ADJ
ajlm-823	89	59	,	,	PUNCT
ajlm-823	89	60	anti	anti	ADJ
ajlm-823	89	61	-	-	ADJ
ajlm-823	89	62	e	e	ADJ
ajlm-823	89	63	,	,	PUNCT
ajlm-823	89	64	anti	anti	ADJ
ajlm-823	89	65	-	-	ADJ
ajlm-823	89	66	e	e	ADJ
ajlm-823	89	67	,	,	PUNCT
ajlm-823	89	68	anti	anti	ADJ
ajlm-823	89	69	-	-	ADJ
ajlm-823	89	70	k	k	ADJ
ajlm-823	89	71	were	be	AUX
ajlm-823	89	72	the	the	DET
ajlm-823	89	73	most	most	ADV
ajlm-823	89	74	common	common	ADJ
ajlm-823	89	75	alloantibodies	alloantibody	NOUN
ajlm-823	89	76	detected	detect	VERB
ajlm-823	89	77	.	.	PUNCT
ajlm-823	90	1	thus	thus	ADV
ajlm-823	90	2	,	,	PUNCT
ajlm-823	90	3	these	these	DET
ajlm-823	90	4	rbc	rbc	PROPN
ajlm-823	90	5	antigens	antigen	NOUN
ajlm-823	90	6	should	should	AUX
ajlm-823	90	7	be	be	AUX
ajlm-823	90	8	included	include	VERB
ajlm-823	90	9	in	in	ADP
ajlm-823	90	10	extended	extended	ADJ
ajlm-823	90	11	blood	blood	NOUN
ajlm-823	90	12	typing	type	VERB
ajlm-823	90	13	to	to	PART
ajlm-823	90	14	detect	detect	VERB
ajlm-823	90	15	alloantibodies	alloantibody	NOUN
ajlm-823	90	16	to	to	ADP
ajlm-823	90	17	these	these	DET
ajlm-823	90	18	groups	group	NOUN
ajlm-823	90	19	.	.	PUNCT
ajlm-823	91	1	warm	warm	ADJ
ajlm-823	91	2	alloantibodies	alloantibody	NOUN
ajlm-823	91	3	(	(	PUNCT
ajlm-823	91	4	often	often	ADV
ajlm-823	91	5	igg	igg	PROPN
ajlm-823	91	6	)	)	PUNCT
ajlm-823	91	7	are	be	AUX
ajlm-823	91	8	of	of	ADP
ajlm-823	91	9	clinical	clinical	ADJ
ajlm-823	91	10	importance	importance	NOUN
ajlm-823	91	11	because	because	SCONJ
ajlm-823	91	12	they	they	PRON
ajlm-823	91	13	haemolyse	haemolyse	VERB
ajlm-823	91	14	red	red	ADJ
ajlm-823	91	15	blood	blood	NOUN
ajlm-823	91	16	cells	cell	NOUN
ajlm-823	91	17	at	at	ADP
ajlm-823	91	18	body	body	NOUN
ajlm-823	91	19	temperature	temperature	NOUN
ajlm-823	91	20	whereas	whereas	SCONJ
ajlm-823	91	21	cold	cold	ADJ
ajlm-823	91	22	antibodies	antibody	NOUN
ajlm-823	91	23	(	(	PUNCT
ajlm-823	91	24	igm	igm	NOUN
ajlm-823	91	25	)	)	PUNCT
ajlm-823	91	26	also	also	ADV
ajlm-823	91	27	known	know	VERB
ajlm-823	91	28	as	as	ADP
ajlm-823	91	29	nuisance	nuisance	ADJ
ajlm-823	91	30	antibodies	antibody	NOUN
ajlm-823	91	31	rarely	rarely	ADV
ajlm-823	91	32	haemolyse	haemolyse	ADJ
ajlm-823	91	33	red	red	ADJ
ajlm-823	91	34	blood	blood	NOUN
ajlm-823	91	35	cells	cell	NOUN
ajlm-823	91	36	in	in	ADP
ajlm-823	91	37	vivo	vivo	NOUN
ajlm-823	91	38	due	due	ADP
ajlm-823	91	39	to	to	ADP
ajlm-823	91	40	temperature	temperature	NOUN
ajlm-823	91	41	inactivation.13	inactivation.13	PROPN
ajlm-823	91	42	in	in	ADP
ajlm-823	91	43	tanzania	tanzania	PROPN
ajlm-823	91	44	,	,	PUNCT
ajlm-823	91	45	the	the	DET
ajlm-823	91	46	lake	lake	NOUN
ajlm-823	91	47	zone	zone	PROPN
ajlm-823	91	48	area	area	NOUN
ajlm-823	91	49	is	be	AUX
ajlm-823	91	50	leading	lead	VERB
ajlm-823	91	51	with	with	ADP
ajlm-823	91	52	scd	scd	PROPN
ajlm-823	91	53	patients	patient	NOUN
ajlm-823	91	54	(	(	PUNCT
ajlm-823	91	55	bmc	bmc	ADJ
ajlm-823	91	56	,	,	PUNCT
ajlm-823	91	57	mwanza	mwanza	ADJ
ajlm-823	91	58	)	)	PUNCT
ajlm-823	91	59	hence	hence	ADV
ajlm-823	91	60	the	the	DET
ajlm-823	91	61	numerous	numerous	ADJ
ajlm-823	91	62	transfusions	transfusion	NOUN
ajlm-823	91	63	as	as	ADP
ajlm-823	91	64	part	part	NOUN
ajlm-823	91	65	of	of	ADP
ajlm-823	91	66	their	their	PRON
ajlm-823	91	67	clinical	clinical	ADJ
ajlm-823	91	68	management14	management14	NOUN
ajlm-823	91	69	.	.	PUNCT
ajlm-823	92	1	thus	thus	ADV
ajlm-823	92	2	,	,	PUNCT
ajlm-823	92	3	the	the	DET
ajlm-823	92	4	prevalence	prevalence	NOUN
ajlm-823	92	5	and	and	CCONJ
ajlm-823	92	6	risk	risk	NOUN
ajlm-823	92	7	factors	factor	NOUN
ajlm-823	92	8	for	for	ADP
ajlm-823	92	9	red	red	ADJ
ajlm-823	92	10	blood	blood	NOUN
ajlm-823	92	11	cell	cell	NOUN
ajlm-823	92	12	alloimmunisation	alloimmunisation	NOUN
ajlm-823	92	13	in	in	ADP
ajlm-823	92	14	this	this	DET
ajlm-823	92	15	locale	locale	NOUN
ajlm-823	92	16	needs	need	VERB
ajlm-823	92	17	to	to	PART
ajlm-823	92	18	be	be	AUX
ajlm-823	92	19	identified	identify	VERB
ajlm-823	92	20	.	.	PUNCT
ajlm-823	93	1	this	this	DET
ajlm-823	93	2	study	study	NOUN
ajlm-823	93	3	found	find	VERB
ajlm-823	93	4	an	an	DET
ajlm-823	93	5	alloimmunisation	alloimmunisation	NOUN
ajlm-823	93	6	rate	rate	NOUN
ajlm-823	93	7	of	of	ADP
ajlm-823	93	8	8.5	8.5	NUM
ajlm-823	93	9	%	%	NOUN
ajlm-823	93	10	among	among	ADP
ajlm-823	93	11	scd	scd	PROPN
ajlm-823	93	12	patients	patient	NOUN
ajlm-823	93	13	at	at	ADP
ajlm-823	93	14	bmc	bmc	PROPN
ajlm-823	93	15	in	in	ADP
ajlm-823	93	16	mwanza	mwanza	PROPN
ajlm-823	93	17	,	,	PUNCT
ajlm-823	93	18	tanzania	tanzania	PROPN
ajlm-823	93	19	,	,	PUNCT
ajlm-823	93	20	but	but	CCONJ
ajlm-823	93	21	found	find	VERB
ajlm-823	93	22	no	no	DET
ajlm-823	93	23	significant	significant	ADJ
ajlm-823	93	24	association	association	NOUN
ajlm-823	93	25	between	between	ADP
ajlm-823	93	26	alloimmunisation	alloimmunisation	NOUN
ajlm-823	93	27	and	and	CCONJ
ajlm-823	93	28	the	the	DET
ajlm-823	93	29	increased	increase	VERB
ajlm-823	93	30	number	number	NOUN
ajlm-823	93	31	of	of	ADP
ajlm-823	93	32	transfusions	transfusion	NOUN
ajlm-823	93	33	.	.	PUNCT
ajlm-823	94	1	limitations	limitation	NOUN
ajlm-823	94	2	multiple	multiple	ADJ
ajlm-823	94	3	transfusion	transfusion	NOUN
ajlm-823	94	4	is	be	AUX
ajlm-823	94	5	a	a	DET
ajlm-823	94	6	risk	risk	NOUN
ajlm-823	94	7	factor	factor	NOUN
ajlm-823	94	8	for	for	ADP
ajlm-823	94	9	alloimmunisation	alloimmunisation	NOUN
ajlm-823	94	10	,	,	PUNCT
ajlm-823	94	11	especially	especially	ADV
ajlm-823	94	12	in	in	ADP
ajlm-823	94	13	sickle	sickle	NOUN
ajlm-823	94	14	cell	cell	NOUN
ajlm-823	94	15	disease	disease	NOUN
ajlm-823	94	16	patients	patient	NOUN
ajlm-823	94	17	.	.	PUNCT
ajlm-823	95	1	however	however	ADV
ajlm-823	95	2	,	,	PUNCT
ajlm-823	95	3	in	in	ADP
ajlm-823	95	4	our	our	PRON
ajlm-823	95	5	study	study	NOUN
ajlm-823	95	6	,	,	PUNCT
ajlm-823	95	7	multiply	multiply	CCONJ
ajlm-823	95	8	transfusion	transfusion	NOUN
ajlm-823	95	9	was	be	AUX
ajlm-823	95	10	not	not	PART
ajlm-823	95	11	significantly	significantly	ADV
ajlm-823	95	12	associated	associate	VERB
ajlm-823	95	13	with	with	ADP
ajlm-823	95	14	alloantibody	alloantibody	PROPN
ajlm-823	95	15	development	development	NOUN
ajlm-823	95	16	.	.	PUNCT
ajlm-823	96	1	this	this	PRON
ajlm-823	96	2	could	could	AUX
ajlm-823	96	3	be	be	AUX
ajlm-823	96	4	,	,	PUNCT
ajlm-823	96	5	in	in	ADP
ajlm-823	96	6	part	part	NOUN
ajlm-823	96	7	,	,	PUNCT
ajlm-823	96	8	due	due	ADP
ajlm-823	96	9	to	to	ADP
ajlm-823	96	10	the	the	DET
ajlm-823	96	11	small	small	ADJ
ajlm-823	96	12	sample	sample	NOUN
ajlm-823	96	13	size	size	NOUN
ajlm-823	96	14	,	,	PUNCT
ajlm-823	96	15	under	under	NOUN
ajlm-823	96	16	-	-	PUNCT
ajlm-823	96	17	reporting	reporting	NOUN
ajlm-823	96	18	and	and	CCONJ
ajlm-823	96	19	maybe	maybe	ADV
ajlm-823	96	20	because	because	SCONJ
ajlm-823	96	21	all	all	DET
ajlm-823	96	22	participants	participant	NOUN
ajlm-823	96	23	had	have	AUX
ajlm-823	96	24	received	receive	VERB
ajlm-823	96	25	blood	blood	NOUN
ajlm-823	96	26	transfusion	transfusion	NOUN
ajlm-823	96	27	at	at	ADP
ajlm-823	96	28	least	least	ADJ
ajlm-823	96	29	once	once	ADV
ajlm-823	96	30	.	.	PUNCT
ajlm-823	97	1	more	more	ADJ
ajlm-823	97	2	than	than	ADP
ajlm-823	97	3	half	half	NOUN
ajlm-823	97	4	of	of	ADP
ajlm-823	97	5	the	the	DET
ajlm-823	97	6	participants	participant	NOUN
ajlm-823	97	7	’	'	PUNCT
ajlm-823	97	8	guardians	guardian	NOUN
ajlm-823	97	9	or	or	CCONJ
ajlm-823	97	10	parents	parent	NOUN
ajlm-823	97	11	could	could	AUX
ajlm-823	97	12	not	not	PART
ajlm-823	97	13	remember	remember	VERB
ajlm-823	97	14	the	the	DET
ajlm-823	97	15	actual	actual	ADJ
ajlm-823	97	16	number	number	NOUN
ajlm-823	97	17	of	of	ADP
ajlm-823	97	18	blood	blood	NOUN
ajlm-823	97	19	transfusions	transfusion	NOUN
ajlm-823	97	20	a	a	DET
ajlm-823	97	21	child	child	NOUN
ajlm-823	97	22	had	have	AUX
ajlm-823	97	23	taken	take	VERB
ajlm-823	97	24	before	before	ADP
ajlm-823	97	25	attending	attend	VERB
ajlm-823	97	26	bmc	bmc	NOUN
ajlm-823	97	27	,	,	PUNCT
ajlm-823	97	28	thus	thus	ADV
ajlm-823	97	29	influencing	influence	VERB
ajlm-823	97	30	our	our	PRON
ajlm-823	97	31	final	final	ADJ
ajlm-823	97	32	results	result	NOUN
ajlm-823	97	33	.	.	PUNCT
ajlm-823	98	1	availability	availability	NOUN
ajlm-823	98	2	of	of	ADP
ajlm-823	98	3	commercial	commercial	ADJ
ajlm-823	98	4	red	red	ADJ
ajlm-823	98	5	cells	cell	NOUN
ajlm-823	98	6	is	be	AUX
ajlm-823	98	7	a	a	DET
ajlm-823	98	8	problem	problem	NOUN
ajlm-823	98	9	because	because	SCONJ
ajlm-823	98	10	there	there	PRON
ajlm-823	98	11	are	be	VERB
ajlm-823	98	12	few	few	ADJ
ajlm-823	98	13	haematological	haematological	ADJ
ajlm-823	98	14	laboratories	laboratory	NOUN
ajlm-823	98	15	worldwide	worldwide	ADV
ajlm-823	98	16	that	that	PRON
ajlm-823	98	17	can	can	AUX
ajlm-823	98	18	manufacture	manufacture	VERB
ajlm-823	98	19	these	these	DET
ajlm-823	98	20	red	red	ADJ
ajlm-823	98	21	cells	cell	NOUN
ajlm-823	98	22	to	to	PART
ajlm-823	98	23	cover	cover	VERB
ajlm-823	98	24	the	the	DET
ajlm-823	98	25	demands	demand	NOUN
ajlm-823	98	26	.	.	PUNCT
ajlm-823	99	1	our	our	PRON
ajlm-823	99	2	antibody	antibody	NOUN
ajlm-823	99	3	screening	screen	VERB
ajlm-823	99	4	/	/	SYM
ajlm-823	99	5	identification	identification	NOUN
ajlm-823	99	6	approach	approach	NOUN
ajlm-823	99	7	might	might	AUX
ajlm-823	99	8	be	be	AUX
ajlm-823	99	9	prohibitive	prohibitive	ADJ
ajlm-823	99	10	for	for	ADP
ajlm-823	99	11	extensive	extensive	ADJ
ajlm-823	99	12	antibody	antibody	NOUN
ajlm-823	99	13	screening	screen	VERB
ajlm-823	99	14	in	in	ADP
ajlm-823	99	15	institutions	institution	NOUN
ajlm-823	99	16	with	with	ADP
ajlm-823	99	17	larger	large	ADJ
ajlm-823	99	18	samples	sample	NOUN
ajlm-823	99	19	requiring	require	VERB
ajlm-823	99	20	shorter	short	ADJ
ajlm-823	99	21	turnaround	turnaround	NOUN
ajlm-823	99	22	time	time	NOUN
ajlm-823	99	23	because	because	SCONJ
ajlm-823	99	24	it	it	PRON
ajlm-823	99	25	is	be	AUX
ajlm-823	99	26	labour	labour	ADV
ajlm-823	99	27	intensive	intensive	ADJ
ajlm-823	99	28	and	and	CCONJ
ajlm-823	99	29	time	time	NOUN
ajlm-823	99	30	-	-	PUNCT
ajlm-823	99	31	consuming	consume	VERB
ajlm-823	99	32	.	.	PUNCT
ajlm-823	100	1	other	other	ADJ
ajlm-823	100	2	methods	method	NOUN
ajlm-823	100	3	like	like	ADP
ajlm-823	100	4	gel	gel	NOUN
ajlm-823	100	5	,	,	PUNCT
ajlm-823	100	6	sprca	sprca	PROPN
ajlm-823	100	7	,	,	PUNCT
ajlm-823	100	8	or	or	CCONJ
ajlm-823	100	9	even	even	ADV
ajlm-823	100	10	automated	automate	VERB
ajlm-823	100	11	methods	method	NOUN
ajlm-823	100	12	can	can	AUX
ajlm-823	100	13	be	be	AUX
ajlm-823	100	14	used	use	VERB
ajlm-823	100	15	as	as	SCONJ
ajlm-823	100	16	these	these	PRON
ajlm-823	100	17	are	be	AUX
ajlm-823	100	18	faster	fast	ADJ
ajlm-823	100	19	,	,	PUNCT
ajlm-823	100	20	thus	thus	ADV
ajlm-823	100	21	reducing	reduce	VERB
ajlm-823	100	22	laboratory	laboratory	NOUN
ajlm-823	100	23	turnaround	turnaround	NOUN
ajlm-823	100	24	time	time	NOUN
ajlm-823	100	25	.	.	PUNCT
ajlm-823	101	1	recommendations	recommendation	NOUN
ajlm-823	101	2	due	due	ADP
ajlm-823	101	3	to	to	ADP
ajlm-823	101	4	the	the	DET
ajlm-823	101	5	common	common	ADJ
ajlm-823	101	6	occurrence	occurrence	NOUN
ajlm-823	101	7	of	of	ADP
ajlm-823	101	8	alloantibodies	alloantibody	NOUN
ajlm-823	101	9	and	and	CCONJ
ajlm-823	101	10	its	its	PRON
ajlm-823	101	11	detection	detection	NOUN
ajlm-823	101	12	within	within	ADP
ajlm-823	101	13	multiply	multiply	NOUN
ajlm-823	101	14	transfused	transfuse	VERB
ajlm-823	101	15	scd	scd	NOUN
ajlm-823	101	16	patients	patient	NOUN
ajlm-823	101	17	in	in	ADP
ajlm-823	101	18	bmc	bmc	PROPN
ajlm-823	101	19	,	,	PUNCT
ajlm-823	101	20	the	the	DET
ajlm-823	101	21	bmc	bmc	PROPN
ajlm-823	101	22	blood	blood	NOUN
ajlm-823	101	23	bank	bank	PROPN
ajlm-823	101	24	and	and	CCONJ
ajlm-823	101	25	zonal	zonal	ADJ
ajlm-823	101	26	national	national	ADJ
ajlm-823	101	27	blood	blood	NOUN
ajlm-823	101	28	transfusion	transfusion	NOUN
ajlm-823	101	29	centre	centre	NOUN
ajlm-823	101	30	should	should	AUX
ajlm-823	101	31	obtain	obtain	VERB
ajlm-823	101	32	facilities	facility	NOUN
ajlm-823	101	33	and	and	CCONJ
ajlm-823	101	34	expertise	expertise	NOUN
ajlm-823	101	35	that	that	PRON
ajlm-823	101	36	will	will	AUX
ajlm-823	101	37	allow	allow	VERB
ajlm-823	101	38	for	for	ADP
ajlm-823	101	39	extensive	extensive	ADJ
ajlm-823	101	40	phenotypic	phenotypic	ADJ
ajlm-823	101	41	blood	blood	NOUN
ajlm-823	101	42	typing	typing	NOUN
ajlm-823	101	43	and	and	CCONJ
ajlm-823	101	44	matching	match	VERB
ajlm-823	101	45	to	to	PART
ajlm-823	101	46	minimise	minimise	VERB
ajlm-823	101	47	the	the	DET
ajlm-823	101	48	development	development	NOUN
ajlm-823	101	49	of	of	ADP
ajlm-823	101	50	alloantibodies	alloantibody	NOUN
ajlm-823	101	51	and	and	CCONJ
ajlm-823	101	52	effectively	effectively	ADV
ajlm-823	101	53	minimize	minimize	VERB
ajlm-823	101	54	risks	risk	NOUN
ajlm-823	101	55	of	of	ADP
ajlm-823	101	56	delayed	delay	VERB
ajlm-823	101	57	haemolytic	haemolytic	ADJ
ajlm-823	101	58	transfusion	transfusion	NOUN
ajlm-823	101	59	reaction	reaction	NOUN
ajlm-823	101	60	in	in	ADP
ajlm-823	101	61	scd	scd	NOUN
ajlm-823	101	62	and	and	CCONJ
ajlm-823	101	63	chronically	chronically	ADV
ajlm-823	101	64	transfused	transfused	ADJ
ajlm-823	101	65	patients	patient	NOUN
ajlm-823	101	66	.	.	PUNCT
ajlm-823	102	1	conclusion	conclusion	VERB
ajlm-823	102	2	the	the	DET
ajlm-823	102	3	rate	rate	NOUN
ajlm-823	102	4	of	of	ADP
ajlm-823	102	5	alloimmunisation	alloimmunisation	NOUN
ajlm-823	102	6	in	in	ADP
ajlm-823	102	7	multiply	multiply	NOUN
ajlm-823	102	8	transfused	transfused	ADJ
ajlm-823	102	9	scd	scd	NOUN
ajlm-823	102	10	patients	patient	NOUN
ajlm-823	102	11	was	be	AUX
ajlm-823	102	12	8.5	8.5	NUM
ajlm-823	102	13	%	%	NOUN
ajlm-823	102	14	and	and	CCONJ
ajlm-823	102	15	higher	high	ADJ
ajlm-823	102	16	than	than	ADP
ajlm-823	102	17	other	other	ADJ
ajlm-823	102	18	studies	study	NOUN
ajlm-823	102	19	from	from	ADP
ajlm-823	102	20	east	east	PROPN
ajlm-823	102	21	and	and	CCONJ
ajlm-823	102	22	west	west	PROPN
ajlm-823	102	23	africa	africa	PROPN
ajlm-823	102	24	.	.	PUNCT
ajlm-823	103	1	thus	thus	ADV
ajlm-823	103	2	,	,	PUNCT
ajlm-823	103	3	there	there	PRON
ajlm-823	103	4	is	be	VERB
ajlm-823	103	5	the	the	DET
ajlm-823	103	6	need	need	NOUN
ajlm-823	103	7	for	for	ADP
ajlm-823	103	8	extensive	extensive	ADJ
ajlm-823	103	9	red	red	ADJ
ajlm-823	103	10	blood	blood	NOUN
ajlm-823	103	11	cell	cell	NOUN
ajlm-823	103	12	screening	screening	NOUN
ajlm-823	103	13	and	and	CCONJ
ajlm-823	103	14	matching	match	VERB
ajlm-823	103	15	to	to	PART
ajlm-823	103	16	minimize	minimize	VERB
ajlm-823	103	17	alloimmunisation	alloimmunisation	NOUN
ajlm-823	103	18	and	and	CCONJ
ajlm-823	103	19	risk	risk	NOUN
ajlm-823	103	20	of	of	ADP
ajlm-823	103	21	delayed	delay	VERB
ajlm-823	103	22	haemolytic	haemolytic	ADJ
ajlm-823	103	23	transfusion	transfusion	NOUN
ajlm-823	103	24	reaction	reaction	NOUN
ajlm-823	103	25	,	,	PUNCT
ajlm-823	103	26	particularly	particularly	ADV
ajlm-823	103	27	in	in	ADP
ajlm-823	103	28	scd	scd	NOUN
ajlm-823	103	29	and	and	CCONJ
ajlm-823	103	30	chronically	chronically	ADV
ajlm-823	103	31	transfused	transfused	ADJ
ajlm-823	103	32	patients	patient	NOUN
ajlm-823	103	33	.	.	PUNCT
ajlm-823	104	1	acknowledgements	acknowledgement	NOUN
ajlm-823	104	2	the	the	DET
ajlm-823	104	3	authors	author	NOUN
ajlm-823	104	4	send	send	VERB
ajlm-823	104	5	a	a	DET
ajlm-823	104	6	special	special	ADJ
ajlm-823	104	7	thanks	thank	NOUN
ajlm-823	104	8	to	to	ADP
ajlm-823	104	9	their	their	PRON
ajlm-823	104	10	families	family	NOUN
ajlm-823	104	11	and	and	CCONJ
ajlm-823	104	12	sarah	sarah	PROPN
ajlm-823	104	13	bhuko	bhuko	PROPN
ajlm-823	104	14	for	for	ADP
ajlm-823	104	15	their	their	PRON
ajlm-823	104	16	endurance	endurance	NOUN
ajlm-823	104	17	and	and	CCONJ
ajlm-823	104	18	unyielding	unyielde	VERB
ajlm-823	104	19	support	support	NOUN
ajlm-823	104	20	during	during	ADP
ajlm-823	104	21	our	our	PRON
ajlm-823	104	22	research	research	NOUN
ajlm-823	104	23	work	work	NOUN
ajlm-823	104	24	.	.	PUNCT
ajlm-823	105	1	the	the	DET
ajlm-823	105	2	authors	author	NOUN
ajlm-823	105	3	acknowledge	acknowledge	VERB
ajlm-823	105	4	the	the	DET
ajlm-823	105	5	support	support	NOUN
ajlm-823	105	6	of	of	ADP
ajlm-823	105	7	lorne	lorne	PROPN
ajlm-823	105	8	laboratories	laboratory	NOUN
ajlm-823	105	9	in	in	ADP
ajlm-823	105	10	the	the	DET
ajlm-823	105	11	united	united	ADJ
ajlm-823	105	12	kingdom	kingdom	NOUN
ajlm-823	105	13	for	for	ADP
ajlm-823	105	14	supplying	supply	VERB
ajlm-823	105	15	reagents	reagent	NOUN
ajlm-823	105	16	for	for	ADP
ajlm-823	105	17	this	this	DET
ajlm-823	105	18	experimental	experimental	ADJ
ajlm-823	105	19	paper	paper	NOUN
ajlm-823	105	20	and	and	CCONJ
ajlm-823	105	21	the	the	DET
ajlm-823	105	22	technical	technical	ADJ
ajlm-823	105	23	support	support	NOUN
ajlm-823	105	24	from	from	ADP
ajlm-823	105	25	bugando	bugando	ADJ
ajlm-823	105	26	referral	referral	ADJ
ajlm-823	105	27	hospital	hospital	PROPN
ajlm-823	105	28	-	-	PUNCT
ajlm-823	105	29	cpl	cpl	PROPN
ajlm-823	105	30	department	department	NOUN
ajlm-823	105	31	.	.	PUNCT
ajlm-823	106	1	the	the	DET
ajlm-823	106	2	authors	author	NOUN
ajlm-823	106	3	also	also	ADV
ajlm-823	106	4	offer	offer	VERB
ajlm-823	106	5	their	their	PRON
ajlm-823	106	6	appreciation	appreciation	NOUN
ajlm-823	106	7	to	to	ADP
ajlm-823	106	8	the	the	DET
ajlm-823	106	9	higher	high	ADJ
ajlm-823	106	10	education	education	NOUN
ajlm-823	106	11	students	student	NOUN
ajlm-823	106	12	loans	loan	NOUN
ajlm-823	106	13	board	board	NOUN
ajlm-823	106	14	for	for	ADP
ajlm-823	106	15	funding	fund	VERB
ajlm-823	106	16	this	this	DET
ajlm-823	106	17	research	research	NOUN
ajlm-823	106	18	work	work	NOUN
ajlm-823	106	19	.	.	PUNCT
ajlm-823	107	1	last	last	ADJ
ajlm-823	107	2	but	but	CCONJ
ajlm-823	107	3	not	not	PART
ajlm-823	107	4	least	least	ADJ
ajlm-823	107	5	,	,	PUNCT
ajlm-823	107	6	the	the	DET
ajlm-823	107	7	authors	author	NOUN
ajlm-823	107	8	would	would	AUX
ajlm-823	107	9	like	like	VERB
ajlm-823	107	10	to	to	PART
ajlm-823	107	11	extend	extend	VERB
ajlm-823	107	12	their	their	PRON
ajlm-823	107	13	sincere	sincere	ADJ
ajlm-823	107	14	gratitude	gratitude	NOUN
ajlm-823	107	15	and	and	CCONJ
ajlm-823	107	16	appreciation	appreciation	NOUN
ajlm-823	107	17	to	to	ADP
ajlm-823	107	18	all	all	DET
ajlm-823	107	19	classmates	classmate	NOUN
ajlm-823	107	20	who	who	PRON
ajlm-823	107	21	helped	help	VERB
ajlm-823	107	22	in	in	ADP
ajlm-823	107	23	one	one	NUM
ajlm-823	107	24	way	way	NOUN
ajlm-823	107	25	or	or	CCONJ
ajlm-823	107	26	another	another	PRON
ajlm-823	107	27	during	during	ADP
ajlm-823	107	28	this	this	DET
ajlm-823	107	29	research	research	NOUN
ajlm-823	107	30	work	work	NOUN
ajlm-823	107	31	.	.	PUNCT
ajlm-823	108	1	competing	compete	VERB
ajlm-823	108	2	interests	interest	NOUN
ajlm-823	108	3	the	the	DET
ajlm-823	108	4	authors	author	NOUN
ajlm-823	108	5	declare	declare	VERB
ajlm-823	108	6	that	that	SCONJ
ajlm-823	108	7	they	they	PRON
ajlm-823	108	8	have	have	VERB
ajlm-823	108	9	no	no	DET
ajlm-823	108	10	financial	financial	ADJ
ajlm-823	108	11	or	or	CCONJ
ajlm-823	108	12	personal	personal	ADJ
ajlm-823	108	13	relationships	relationship	NOUN
ajlm-823	108	14	that	that	PRON
ajlm-823	108	15	may	may	AUX
ajlm-823	108	16	have	have	AUX
ajlm-823	108	17	inappropriately	inappropriately	ADV
ajlm-823	108	18	influenced	influence	VERB
ajlm-823	108	19	them	they	PRON
ajlm-823	108	20	in	in	ADP
ajlm-823	108	21	writing	write	VERB
ajlm-823	108	22	this	this	DET
ajlm-823	108	23	paper	paper	NOUN
ajlm-823	108	24	.	.	PUNCT
ajlm-823	109	1	authors	author	NOUN
ajlm-823	109	2	’	’	PART
ajlm-823	109	3	contributions	contribution	NOUN
ajlm-823	109	4	j.o.b	j.o.b	PROPN
ajlm-823	109	5	.	.	PUNCT
ajlm-823	110	1	and	and	CCONJ
ajlm-823	110	2	e.t	e.t	PROPN
ajlm-823	110	3	.	.	PROPN
ajlm-823	110	4	conceived	conceive	VERB
ajlm-823	110	5	and	and	CCONJ
ajlm-823	110	6	designed	design	VERB
ajlm-823	110	7	the	the	DET
ajlm-823	110	8	study	study	NOUN
ajlm-823	110	9	.	.	PUNCT
ajlm-823	111	1	j.o.b	j.o.b	PROPN
ajlm-823	111	2	,	,	PUNCT
ajlm-823	111	3	e.t	e.t	PROPN
ajlm-823	111	4	.	.	PROPN
ajlm-823	111	5	and	and	CCONJ
ajlm-823	111	6	m.c	m.c	PROPN
ajlm-823	111	7	.	.	PROPN
ajlm-823	111	8	contributed	contribute	VERB
ajlm-823	111	9	reagents	reagent	NOUN
ajlm-823	111	10	/	/	SYM
ajlm-823	111	11	materials	material	NOUN
ajlm-823	111	12	.	.	PUNCT
ajlm-823	112	1	j.o.b	j.o.b	PROPN
ajlm-823	112	2	.	.	PUNCT
ajlm-823	113	1	and	and	CCONJ
ajlm-823	113	2	m.c	m.c	PROPN
ajlm-823	113	3	.	.	PROPN
ajlm-823	113	4	collected	collect	VERB
ajlm-823	113	5	the	the	DET
ajlm-823	113	6	data	datum	NOUN
ajlm-823	113	7	,	,	PUNCT
ajlm-823	113	8	and	and	CCONJ
ajlm-823	113	9	the	the	DET
ajlm-823	113	10	data	datum	NOUN
ajlm-823	113	11	analysis	analysis	NOUN
ajlm-823	113	12	was	be	AUX
ajlm-823	113	13	done	do	VERB
ajlm-823	113	14	by	by	ADP
ajlm-823	113	15	j.o.b	j.o.b	PROPN
ajlm-823	113	16	.	.	PUNCT
ajlm-823	114	1	and	and	CCONJ
ajlm-823	114	2	e.t	e.t	PROPN
ajlm-823	114	3	.	.	PROPN
ajlm-823	114	4	j.o.b	j.o.b	PROPN
ajlm-823	114	5	.	.	PUNCT
ajlm-823	114	6	wrote	write	VERB
ajlm-823	114	7	the	the	DET
ajlm-823	114	8	manuscript	manuscript	NOUN
ajlm-823	114	9	.	.	PUNCT
ajlm-823	115	1	all	all	DET
ajlm-823	115	2	authors	author	NOUN
ajlm-823	115	3	read	read	VERB
ajlm-823	115	4	and	and	CCONJ
ajlm-823	115	5	approved	approve	VERB
ajlm-823	115	6	the	the	DET
ajlm-823	115	7	final	final	ADJ
ajlm-823	115	8	manuscript	manuscript	NOUN
ajlm-823	115	9	.	.	PUNCT
ajlm-823	116	1	sources	source	NOUN
ajlm-823	116	2	of	of	ADP
ajlm-823	116	3	support	support	NOUN
ajlm-823	116	4	this	this	DET
ajlm-823	116	5	study	study	NOUN
ajlm-823	116	6	was	be	AUX
ajlm-823	116	7	funded	fund	VERB
ajlm-823	116	8	by	by	ADP
ajlm-823	116	9	higher	high	ADJ
ajlm-823	116	10	education	education	NOUN
ajlm-823	116	11	students	student	NOUN
ajlm-823	116	12	loans	loan	NOUN
ajlm-823	116	13	board	board	PROPN
ajlm-823	116	14	,	,	PUNCT
ajlm-823	116	15	as	as	ADP
ajlm-823	116	16	a	a	DET
ajlm-823	116	17	part	part	NOUN
ajlm-823	116	18	of	of	ADP
ajlm-823	116	19	the	the	DET
ajlm-823	116	20	degree	degree	NOUN
ajlm-823	116	21	awarded	award	VERB
ajlm-823	116	22	to	to	PART
ajlm-823	116	23	jeffer	jeffer	VERB
ajlm-823	116	24	bhuko	bhuko	PROPN
ajlm-823	116	25	by	by	ADP
ajlm-823	116	26	catholic	catholic	PROPN
ajlm-823	116	27	university	university	PROPN
ajlm-823	116	28	of	of	ADP
ajlm-823	116	29	health	health	PROPN
ajlm-823	116	30	and	and	CCONJ
ajlm-823	116	31	allied	ally	VERB
ajlm-823	116	32	sciences	science	NOUN
ajlm-823	116	33	,	,	PUNCT
ajlm-823	116	34	mwanza	mwanza	PROPN
ajlm-823	116	35	,	,	PUNCT
ajlm-823	116	36	tanzania	tanzania	PROPN
ajlm-823	116	37	.	.	PUNCT
ajlm-823	117	1	reagents	reagent	NOUN
ajlm-823	117	2	are	be	AUX
ajlm-823	117	3	commercial	commercial	ADJ
ajlm-823	117	4	red	red	ADJ
ajlm-823	117	5	cells	cell	NOUN
ajlm-823	117	6	which	which	PRON
ajlm-823	117	7	were	be	AUX
ajlm-823	117	8	purchased	purchase	VERB
ajlm-823	117	9	from	from	ADP
ajlm-823	117	10	lorne	lorne	PROPN
ajlm-823	117	11	laboratories	laboratories	PROPN
ajlm-823	117	12	uk	uk	PROPN
ajlm-823	117	13	,	,	PUNCT
ajlm-823	117	14	and	and	CCONJ
ajlm-823	117	15	these	these	PRON
ajlm-823	117	16	were	be	AUX
ajlm-823	117	17	purchased	purchase	VERB
ajlm-823	117	18	with	with	ADP
ajlm-823	117	19	a	a	DET
ajlm-823	117	20	fund	fund	NOUN
ajlm-823	117	21	from	from	ADP
ajlm-823	117	22	the	the	DET
ajlm-823	117	23	higher	high	ADJ
ajlm-823	117	24	education	education	NOUN
ajlm-823	117	25	students	student	NOUN
ajlm-823	117	26	loans	loan	NOUN
ajlm-823	117	27	board	board	PROPN
ajlm-823	117	28	.	.	PUNCT
ajlm-823	118	1	data	datum	NOUN
ajlm-823	118	2	availability	availability	NOUN
ajlm-823	118	3	data	datum	NOUN
ajlm-823	118	4	sharing	sharing	NOUN
ajlm-823	118	5	does	do	AUX
ajlm-823	118	6	not	not	PART
ajlm-823	118	7	apply	apply	VERB
ajlm-823	118	8	to	to	ADP
ajlm-823	118	9	this	this	DET
ajlm-823	118	10	article	article	NOUN
ajlm-823	118	11	as	as	SCONJ
ajlm-823	118	12	no	no	DET
ajlm-823	118	13	new	new	ADJ
ajlm-823	118	14	data	datum	NOUN
ajlm-823	118	15	were	be	AUX
ajlm-823	118	16	created	create	VERB
ajlm-823	118	17	or	or	CCONJ
ajlm-823	118	18	analysed	analyse	VERB
ajlm-823	118	19	in	in	ADP
ajlm-823	118	20	this	this	DET
ajlm-823	118	21	study	study	NOUN
ajlm-823	118	22	.	.	PUNCT
ajlm-823	119	1	disclaimer	disclaimer	VERB
ajlm-823	119	2	the	the	DET
ajlm-823	119	3	views	view	NOUN
ajlm-823	119	4	and	and	CCONJ
ajlm-823	119	5	opinions	opinion	NOUN
ajlm-823	119	6	expressed	express	VERB
ajlm-823	119	7	in	in	ADP
ajlm-823	119	8	this	this	DET
ajlm-823	119	9	article	article	NOUN
ajlm-823	119	10	are	be	AUX
ajlm-823	119	11	those	those	PRON
ajlm-823	119	12	of	of	ADP
ajlm-823	119	13	the	the	DET
ajlm-823	119	14	authors	author	NOUN
ajlm-823	119	15	and	and	CCONJ
ajlm-823	119	16	do	do	AUX
ajlm-823	119	17	not	not	PART
ajlm-823	119	18	necessarily	necessarily	ADV
ajlm-823	119	19	reflect	reflect	VERB
ajlm-823	119	20	the	the	DET
ajlm-823	119	21	official	official	ADJ
ajlm-823	119	22	policy	policy	NOUN
ajlm-823	119	23	or	or	CCONJ
ajlm-823	119	24	position	position	NOUN
ajlm-823	119	25	of	of	ADP
ajlm-823	119	26	any	any	DET
ajlm-823	119	27	affiliated	affiliated	ADJ
ajlm-823	119	28	agency	agency	NOUN
ajlm-823	119	29	of	of	ADP
ajlm-823	119	30	the	the	DET
ajlm-823	119	31	authors	author	NOUN
ajlm-823	119	32	.	.	PUNCT
ajlm-823	120	1	references	reference	NOUN
ajlm-823	120	2	kangiwa	kangiwa	VERB
ajlm-823	120	3	u	u	PROPN
ajlm-823	120	4	,	,	PUNCT
ajlm-823	120	5	ibegbulam	ibegbulam	NOUN
ajlm-823	120	6	o	o	NOUN
ajlm-823	120	7	,	,	PUNCT
ajlm-823	120	8	ocheni	ocheni	PROPN
ajlm-823	120	9	s	s	PART
ajlm-823	120	10	,	,	PUNCT
ajlm-823	120	11	madu	madu	NOUN
ajlm-823	120	12	a	a	PRON
ajlm-823	120	13	,	,	PUNCT
ajlm-823	120	14	mohammed	mohammed	PROPN
ajlm-823	120	15	n.	n.	PROPN
ajlm-823	120	16	pattern	pattern	NOUN
ajlm-823	120	17	and	and	CCONJ
ajlm-823	120	18	prevelence	prevelence	NOUN
ajlm-823	120	19	of	of	ADP
ajlm-823	120	20	alloimmunization	alloimmunization	NOUN
ajlm-823	120	21	in	in	ADP
ajlm-823	120	22	multiply	multiply	NOUN
ajlm-823	120	23	transfused	transfused	ADJ
ajlm-823	120	24	patients	patient	NOUN
ajlm-823	120	25	with	with	ADP
ajlm-823	120	26	sickle	sickle	NOUN
ajlm-823	120	27	cell	cell	NOUN
ajlm-823	120	28	disease	disease	NOUN
ajlm-823	120	29	in	in	ADP
ajlm-823	120	30	nigeria	nigeria	PROPN
ajlm-823	120	31	.	.	PUNCT
ajlm-823	121	1	biomarker	biomarker	NOUN
ajlm-823	121	2	res	re	NOUN
ajlm-823	121	3	.	.	PUNCT
ajlm-823	122	1	2015;3(1):26	2015;3(1):26	NUM
ajlm-823	122	2	.	.	NOUN
ajlm-823	122	3	https://doi.org/10.1186/s40364-015-0050-3	https://doi.org/10.1186/s40364-015-0050-3	NUM
ajlm-823	122	4	yazdanbakhsh	yazdanbakhsh	PROPN
ajlm-823	122	5	k	k	PROPN
ajlm-823	122	6	,	,	PUNCT
ajlm-823	122	7	ware	ware	VERB
ajlm-823	122	8	re	re	PROPN
ajlm-823	122	9	,	,	PUNCT
ajlm-823	122	10	noizat	noizat	NOUN
ajlm-823	122	11	-	-	PUNCT
ajlm-823	122	12	pirenne	pirenne	PROPN
ajlm-823	122	13	f.	f.	PROPN
ajlm-823	122	14	red	red	PROPN
ajlm-823	122	15	blood	blood	NOUN
ajlm-823	122	16	cell	cell	NOUN
ajlm-823	122	17	alloimmunization	alloimmunization	NOUN
ajlm-823	122	18	in	in	ADP
ajlm-823	122	19	sickle	sickle	NOUN
ajlm-823	122	20	cell	cell	NOUN
ajlm-823	122	21	disease	disease	NOUN
ajlm-823	122	22	:	:	PUNCT
ajlm-823	122	23	pathophysiology	pathophysiology	NOUN
ajlm-823	122	24	,	,	PUNCT
ajlm-823	122	25	risk	risk	NOUN
ajlm-823	122	26	factors	factor	NOUN
ajlm-823	122	27	,	,	PUNCT
ajlm-823	122	28	and	and	CCONJ
ajlm-823	122	29	transfusion	transfusion	NOUN
ajlm-823	122	30	management	management	NOUN
ajlm-823	122	31	.	.	PUNCT
ajlm-823	123	1	blood	blood	NOUN
ajlm-823	123	2	.	.	PUNCT
ajlm-823	124	1	2012;120(3):528–537	2012;120(3):528–537	X
ajlm-823	124	2	.	.	PUNCT
ajlm-823	124	3	https://doi.org/10.1182/blood-2011-11-327361	https://doi.org/10.1182/blood-2011-11-327361	NOUN
ajlm-823	124	4	ugwu	ugwu	ADJ
ajlm-823	124	5	n	n	CCONJ
ajlm-823	124	6	,	,	PUNCT
ajlm-823	124	7	awodu	awodu	NOUN
ajlm-823	124	8	o	o	NOUN
ajlm-823	124	9	,	,	PUNCT
ajlm-823	124	10	bazuaye	bazuaye	VERB
ajlm-823	124	11	g	g	NOUN
ajlm-823	124	12	,	,	PUNCT
ajlm-823	124	13	okoye	okoye	PROPN
ajlm-823	124	14	a.	a.	NOUN
ajlm-823	124	15	red	red	PROPN
ajlm-823	124	16	cell	cell	NOUN
ajlm-823	124	17	alloimmunization	alloimmunization	NOUN
ajlm-823	124	18	in	in	ADP
ajlm-823	124	19	multi‑transfused	multi‑transfuse	VERB
ajlm-823	124	20	patients	patient	NOUN
ajlm-823	124	21	with	with	ADP
ajlm-823	124	22	sickle	sickle	PROPN
ajlm-823	124	23	cell	cell	NOUN
ajlm-823	124	24	anemia	anemia	NOUN
ajlm-823	124	25	in	in	ADP
ajlm-823	124	26	benin	benin	PROPN
ajlm-823	124	27	city	city	PROPN
ajlm-823	124	28	,	,	PUNCT
ajlm-823	124	29	nigeria	nigeria	PROPN
ajlm-823	124	30	.	.	PUNCT
ajlm-823	125	1	nigerian	nigerian	PROPN
ajlm-823	125	2	j	j	PROPN
ajlm-823	125	3	clin	clin	PROPN
ajlm-823	125	4	pract	pract	PROPN
ajlm-823	125	5	.	.	PUNCT
ajlm-823	126	1	2015;18(4):522–526	2015;18(4):522–526	X
ajlm-823	126	2	.	.	PUNCT
ajlm-823	127	1	https://doi.org/10.4103/1119-3077.154204	https://doi.org/10.4103/1119-3077.154204	PROPN
ajlm-823	127	2	heddle	heddle	NOUN
ajlm-823	127	3	nm	nm	PROPN
ajlm-823	127	4	,	,	PUNCT
ajlm-823	127	5	soutar	soutar	PROPN
ajlm-823	127	6	rl	rl	PROPN
ajlm-823	127	7	,	,	PUNCT
ajlm-823	127	8	o’hoski	o’hoski	PROPN
ajlm-823	127	9	pl	pl	PROPN
ajlm-823	127	10	,	,	PUNCT
ajlm-823	127	11	et	et	PROPN
ajlm-823	127	12	al	al	PROPN
ajlm-823	127	13	.	.	PUNCT
ajlm-823	128	1	a	a	DET
ajlm-823	128	2	prospective	prospective	ADJ
ajlm-823	128	3	study	study	NOUN
ajlm-823	128	4	to	to	PART
ajlm-823	128	5	determine	determine	VERB
ajlm-823	128	6	the	the	DET
ajlm-823	128	7	frequency	frequency	NOUN
ajlm-823	128	8	and	and	CCONJ
ajlm-823	128	9	clinical	clinical	ADJ
ajlm-823	128	10	significance	significance	NOUN
ajlm-823	128	11	of	of	ADP
ajlm-823	128	12	alloimmunisation	alloimmunisation	NOUN
ajlm-823	128	13	post	post	NOUN
ajlm-823	128	14	-	-	NOUN
ajlm-823	128	15	transfusion	transfusion	NOUN
ajlm-823	128	16	.	.	PUNCT
ajlm-823	129	1	br	br	X
ajlm-823	129	2	j	j	PROPN
ajlm-823	129	3	haematol	haematol	NOUN
ajlm-823	129	4	.	.	PUNCT
ajlm-823	130	1	1995;91(4):1000–1005	1995;91(4):1000–1005	NUM
ajlm-823	130	2	.	.	PUNCT
ajlm-823	131	1	https://doi.org/10.1111/j.1365-2141.1995.tb05425.x	https://doi.org/10.1111/j.1365-2141.1995.tb05425.x	AUX
ajlm-823	131	2	goding	gode	VERB
ajlm-823	131	3	jw	jw	PROPN
ajlm-823	131	4	.	.	PROPN
ajlm-823	131	5	monoclonal	monoclonal	NOUN
ajlm-823	131	6	antibodies	antibodie	VERB
ajlm-823	131	7	:	:	PUNCT
ajlm-823	131	8	principles	principle	NOUN
ajlm-823	131	9	and	and	CCONJ
ajlm-823	131	10	practice	practice	NOUN
ajlm-823	131	11	.	.	PUNCT
ajlm-823	132	1	london	london	PROPN
ajlm-823	132	2	:	:	PUNCT
ajlm-823	132	3	academic	academic	ADJ
ajlm-823	132	4	press	press	NOUN
ajlm-823	132	5	;	;	PUNCT
ajlm-823	132	6	1996	1996	NUM
ajlm-823	132	7	.	.	PUNCT
ajlm-823	133	1	https://books.google.co.tz/books?hl=en&lr=&id=jpk4zy4cnqqc&oi=fnd&pg=pp1&dq=goding+jw.+monoclonal+antibodies:+principles+and+practice.+academic+press&ots=4eztgtmgfr&sig=pwmoltkhu-af2qanx7pmtox3oy4&redir_esc=y#v=onepage&q=goding%20jw.%20monoclonal%20antibodies%3a%20principles%20and%20practice.%20academic%20press&f=false	https://books.google.co.tz/books?hl=en&lr=&id=jpk4zy4cnqqc&oi=fnd&pg=pp1&dq=goding+jw.+monoclonal+antibodies:+principles+and+practice.+academic+press&ots=4eztgtmgfr&sig=pwmoltkhu-af2qanx7pmtox3oy4&redir_esc=y#v=onepage&q=goding%20jw.%20monoclonal%20antibodies%3a%20principles%20and%20practice.%20academic%20press&f=false	PROPN
ajlm-823	133	2	miller	miller	PROPN
ajlm-823	133	3	st	st	PROPN
ajlm-823	133	4	,	,	PUNCT
ajlm-823	133	5	kimr	kimr	PROPN
ajlm-823	133	6	d	d	PROPN
ajlm-823	133	7	,	,	PUNCT
ajlm-823	133	8	styles	style	NOUN
ajlm-823	133	9	la	la	ADJ
ajlm-823	133	10	,	,	PUNCT
ajlm-823	133	11	dampier	dampier	PROPN
ajlm-823	133	12	cd	cd	PROPN
ajlm-823	133	13	,	,	PUNCT
ajlm-823	133	14	roseff	roseff	PROPN
ajlm-823	133	15	sd	sd	PROPN
ajlm-823	133	16	.	.	PUNCT
ajlm-823	133	17	red	red	ADJ
ajlm-823	133	18	blood	blood	NOUN
ajlm-823	133	19	cell	cell	NOUN
ajlm-823	133	20	alloimmunization	alloimmunization	NOUN
ajlm-823	133	21	in	in	ADP
ajlm-823	133	22	sickle	sickle	NOUN
ajlm-823	133	23	cell	cell	NOUN
ajlm-823	133	24	disease	disease	NOUN
ajlm-823	133	25	:	:	PUNCT
ajlm-823	133	26	prevalence	prevalence	NOUN
ajlm-823	133	27	in	in	ADP
ajlm-823	133	28	2010	2010	NUM
ajlm-823	133	29	.	.	PUNCT
ajlm-823	134	1	transfusion	transfusion	NOUN
ajlm-823	134	2	.	.	PUNCT
ajlm-823	135	1	2013;53(4):704–709	2013;53(4):704–709	X
ajlm-823	135	2	.	.	PUNCT
ajlm-823	136	1	https://doi.org/10.1111/j.1537-2995.2012.03796.x	https://doi.org/10.1111/j.1537-2995.2012.03796.x	PROPN
ajlm-823	136	2	bashawri	bashawri	PROPN
ajlm-823	136	3	l.	l.	PROPN
ajlm-823	136	4	red	red	PROPN
ajlm-823	136	5	cell	cell	PROPN
ajlm-823	136	6	alloimmunization	alloimmunization	NOUN
ajlm-823	136	7	in	in	ADP
ajlm-823	136	8	sickle	sickle	NOUN
ajlm-823	136	9	-	-	PUNCT
ajlm-823	136	10	cell	cell	NOUN
ajlm-823	136	11	anaemia	anaemia	NOUN
ajlm-823	136	12	patients	patient	NOUN
ajlm-823	136	13	.	.	PUNCT
ajlm-823	137	1	eastern	eastern	PROPN
ajlm-823	137	2	mediterranean	mediterranean	PROPN
ajlm-823	137	3	health	health	PROPN
ajlm-823	137	4	j.	j.	PROPN
ajlm-823	137	5	2007;13(5):1181–1189	2007;13(5):1181–1189	PROPN
ajlm-823	137	6	.	.	PUNCT
ajlm-823	138	1	https://doi.org/10.26719/2007.13.5.1181	https://doi.org/10.26719/2007.13.5.1181	PROPN
ajlm-823	138	2	chou	chou	PROPN
ajlm-823	138	3	st	st	PROPN
ajlm-823	138	4	,	,	PUNCT
ajlm-823	138	5	jackson	jackson	PROPN
ajlm-823	138	6	t	t	PROPN
ajlm-823	138	7	,	,	PUNCT
ajlm-823	138	8	vege	vege	PROPN
ajlm-823	138	9	s	s	PROPN
ajlm-823	138	10	,	,	PUNCT
ajlm-823	138	11	smith	smith	PROPN
ajlm-823	138	12	-	-	PUNCT
ajlm-823	138	13	whitley	whitley	PROPN
ajlm-823	138	14	k	k	PROPN
ajlm-823	138	15	,	,	PUNCT
ajlm-823	138	16	friedman	friedman	PROPN
ajlm-823	138	17	df	df	PROPN
ajlm-823	138	18	,	,	PUNCT
ajlm-823	138	19	westhoff	westhoff	PROPN
ajlm-823	138	20	cm	cm	PROPN
ajlm-823	138	21	.	.	PUNCT
ajlm-823	139	1	high	high	ADJ
ajlm-823	139	2	prevalence	prevalence	NOUN
ajlm-823	139	3	of	of	ADP
ajlm-823	139	4	red	red	ADJ
ajlm-823	139	5	blood	blood	NOUN
ajlm-823	139	6	cell	cell	NOUN
ajlm-823	139	7	alloimmunization	alloimmunization	NOUN
ajlm-823	139	8	in	in	ADP
ajlm-823	139	9	sickle	sickle	NOUN
ajlm-823	139	10	cell	cell	NOUN
ajlm-823	139	11	disease	disease	NOUN
ajlm-823	139	12	despite	despite	SCONJ
ajlm-823	139	13	transfusion	transfusion	NOUN
ajlm-823	139	14	from	from	ADP
ajlm-823	139	15	rh	rh	PROPN
ajlm-823	139	16	-	-	PUNCT
ajlm-823	139	17	matched	match	VERB
ajlm-823	139	18	minority	minority	NOUN
ajlm-823	139	19	donors	donor	NOUN
ajlm-823	139	20	.	.	PUNCT
ajlm-823	140	1	blood	blood	NOUN
ajlm-823	140	2	.	.	PUNCT
ajlm-823	141	1	am	be	AUX
ajlm-823	141	2	soc	soc	NOUN
ajlm-823	141	3	hematol	hematol	NOUN
ajlm-823	141	4	.	.	PUNCT
ajlm-823	142	1	2013;122:1062–1071	2013;122:1062–1071	NUM
ajlm-823	142	2	.	.	PUNCT
ajlm-823	143	1	https://doi.org/10.1182/blood-2013-03-490623	https://doi.org/10.1182/blood-2013-03-490623	PROPN
ajlm-823	143	2	natukunda	natukunda	PROPN
ajlm-823	143	3	b	b	PROPN
ajlm-823	143	4	,	,	PUNCT
ajlm-823	143	5	schonewille	schonewille	NOUN
ajlm-823	143	6	h	h	NOUN
ajlm-823	143	7	,	,	PUNCT
ajlm-823	143	8	ndugwa	ndugwa	NOUN
ajlm-823	143	9	c	c	NOUN
ajlm-823	143	10	,	,	PUNCT
ajlm-823	143	11	brand	brand	NOUN
ajlm-823	143	12	a.	a.	NOUN
ajlm-823	143	13	red	red	PROPN
ajlm-823	143	14	blood	blood	NOUN
ajlm-823	143	15	cell	cell	NOUN
ajlm-823	143	16	alloimmunization	alloimmunization	NOUN
ajlm-823	143	17	in	in	ADP
ajlm-823	143	18	sickle	sickle	NOUN
ajlm-823	143	19	cell	cell	NOUN
ajlm-823	143	20	disease	disease	NOUN
ajlm-823	143	21	patients	patient	NOUN
ajlm-823	143	22	in	in	ADP
ajlm-823	143	23	uganda	uganda	PROPN
ajlm-823	143	24	.	.	PUNCT
ajlm-823	144	1	transfusion	transfusion	NOUN
ajlm-823	144	2	.	.	PUNCT
ajlm-823	145	1	2010;50(1):20–25	2010;50(1):20–25	X
ajlm-823	145	2	.	.	PUNCT
ajlm-823	145	3	https://doi.org/10.1111/j.1537-2995.2009.02435	https://doi.org/10.1111/j.1537-2995.2009.02435	VERB
ajlm-823	145	4	meda	meda	NOUN
ajlm-823	145	5	e	e	NOUN
ajlm-823	145	6	,	,	PUNCT
ajlm-823	145	7	magesa	magesa	PROPN
ajlm-823	145	8	p	p	PROPN
ajlm-823	145	9	,	,	PUNCT
ajlm-823	145	10	marlow	marlow	PROPN
ajlm-823	145	11	t	t	PROPN
ajlm-823	145	12	,	,	PUNCT
ajlm-823	145	13	reid	reid	PROPN
ajlm-823	145	14	c	c	PROPN
ajlm-823	145	15	,	,	PUNCT
ajlm-823	145	16	roberts	roberts	PROPN
ajlm-823	145	17	d	d	PROPN
ajlm-823	145	18	,	,	PUNCT
ajlm-823	145	19	makani	makani	PROPN
ajlm-823	145	20	j.	j.	PROPN
ajlm-823	145	21	red	red	PROPN
ajlm-823	145	22	blood	blood	NOUN
ajlm-823	145	23	cell	cell	NOUN
ajlm-823	145	24	alloimmunization	alloimmunization	NOUN
ajlm-823	145	25	in	in	ADP
ajlm-823	145	26	sickle	sickle	NOUN
ajlm-823	145	27	cell	cell	NOUN
ajlm-823	145	28	disease	disease	NOUN
ajlm-823	145	29	patients	patient	NOUN
ajlm-823	145	30	in	in	ADP
ajlm-823	145	31	tanzania	tanzania	PROPN
ajlm-823	145	32	.	.	PUNCT
ajlm-823	146	1	east	east	PROPN
ajlm-823	146	2	afr	afr	PROPN
ajlm-823	146	3	j	j	PROPN
ajlm-823	146	4	public	public	PROPN
ajlm-823	146	5	health	health	NOUN
ajlm-823	146	6	.	.	PUNCT
ajlm-823	147	1	2014;11(2):775–780	2014;11(2):775–780	NUM
ajlm-823	147	2	.	.	PUNCT
ajlm-823	147	3	https://doi.org/10.1016/j.ijans.2015.08.002	https://doi.org/10.1016/j.ijans.2015.08.002	PROPN
ajlm-823	147	4	ambrose	ambrose	PROPN
ajlm-823	147	5	ee	ee	PROPN
ajlm-823	147	6	,	,	PUNCT
ajlm-823	147	7	makani	makani	PROPN
ajlm-823	147	8	j	j	PROPN
ajlm-823	147	9	,	,	PUNCT
ajlm-823	147	10	chami	chami	NOUN
ajlm-823	147	11	n	n	CCONJ
ajlm-823	147	12	,	,	PUNCT
ajlm-823	147	13	et	et	PROPN
ajlm-823	147	14	al	al	PROPN
ajlm-823	147	15	.	.	PROPN
ajlm-823	147	16	high	high	ADJ
ajlm-823	147	17	birth	birth	NOUN
ajlm-823	147	18	prevalence	prevalence	NOUN
ajlm-823	147	19	of	of	ADP
ajlm-823	147	20	sickle	sickle	NOUN
ajlm-823	147	21	cell	cell	NOUN
ajlm-823	147	22	disease	disease	NOUN
ajlm-823	147	23	in	in	ADP
ajlm-823	147	24	northwestern	northwestern	ADJ
ajlm-823	147	25	tanzania	tanzania	PROPN
ajlm-823	147	26	.	.	PUNCT
ajlm-823	148	1	pediatr	pediatr	ADJ
ajlm-823	148	2	blood	blood	NOUN
ajlm-823	148	3	cancer	cancer	NOUN
ajlm-823	148	4	.	.	PUNCT
ajlm-823	149	1	2018;65(1):e26735	2018;65(1):e26735	X
ajlm-823	149	2	.	.	X
ajlm-823	150	1	https://doi.org/10.1002/pbc.26735	https://doi.org/10.1002/pbc.26735	PROPN
ajlm-823	150	2	sihler	sihler	PROPN
ajlm-823	150	3	kc	kc	PROPN
ajlm-823	150	4	,	,	PUNCT
ajlm-823	150	5	napolitano	napolitano	PROPN
ajlm-823	150	6	lm	lm	PROPN
ajlm-823	150	7	.	.	PUNCT
ajlm-823	150	8	complications	complication	NOUN
ajlm-823	150	9	of	of	ADP
ajlm-823	150	10	massive	massive	ADJ
ajlm-823	150	11	transfusion	transfusion	NOUN
ajlm-823	150	12	.	.	PUNCT
ajlm-823	151	1	vol	vol	NOUN
ajlm-823	151	2	.	.	PROPN
ajlm-823	151	3	137	137	NUM
ajlm-823	151	4	,	,	PUNCT
ajlm-823	151	5	chest	chest	NOUN
ajlm-823	151	6	.	.	PUNCT
ajlm-823	152	1	american	american	PROPN
ajlm-823	152	2	college	college	PROPN
ajlm-823	152	3	of	of	ADP
ajlm-823	152	4	chest	chest	NOUN
ajlm-823	152	5	physicians	physician	NOUN
ajlm-823	152	6	;	;	PUNCT
ajlm-823	152	7	2010	2010	NUM
ajlm-823	152	8	.	.	PUNCT
ajlm-823	153	1	p.	p.	NOUN
ajlm-823	153	2	209–220	209–220	NUM
ajlm-823	153	3	.	.	PUNCT
ajlm-823	154	1	https://doi.org/10.1378/chest.09-0252	https://doi.org/10.1378/chest.09-0252	PROPN
ajlm-823	154	2	sokol	sokol	PROPN
ajlm-823	154	3	rj	rj	PROPN
ajlm-823	154	4	,	,	PUNCT
ajlm-823	154	5	hewitt	hewitt	PROPN
ajlm-823	154	6	s	s	PROPN
ajlm-823	154	7	,	,	PUNCT
ajlm-823	154	8	stamps	stamp	NOUN
ajlm-823	154	9	bk	bk	VERB
ajlm-823	154	10	.	.	PUNCT
ajlm-823	154	11	autoimmune	autoimmune	ADJ
ajlm-823	154	12	haemolysis	haemolysis	PROPN
ajlm-823	154	13	:	:	PUNCT
ajlm-823	154	14	mixed	mixed	ADJ
ajlm-823	154	15	warm	warm	ADJ
ajlm-823	154	16	and	and	CCONJ
ajlm-823	154	17	cold	cold	ADJ
ajlm-823	154	18	antibody	antibody	NOUN
ajlm-823	154	19	type	type	NOUN
ajlm-823	154	20	.	.	PUNCT
ajlm-823	155	1	acta	acta	PROPN
ajlm-823	155	2	haematol	haematol	NOUN
ajlm-823	156	1	[	[	X
ajlm-823	156	2	internet	internet	NOUN
ajlm-823	156	3	]	]	PUNCT
ajlm-823	156	4	.	.	PUNCT
ajlm-823	157	1	1983;69(4):266–274	1983;69(4):266–274	NUM
ajlm-823	157	2	.	.	PUNCT
ajlm-823	158	1	https://doi.org/10.1159/000206903	https://doi.org/10.1159/000206903	VERB
ajlm-823	158	2	thakral	thakral	PROPN
ajlm-823	158	3	b	b	NOUN
ajlm-823	158	4	,	,	PUNCT
ajlm-823	158	5	saluja	saluja	PROPN
ajlm-823	158	6	k	k	PROPN
ajlm-823	158	7	,	,	PUNCT
ajlm-823	158	8	sharma	sharma	PROPN
ajlm-823	158	9	rr	rr	PROPN
ajlm-823	158	10	,	,	PUNCT
ajlm-823	158	11	marwaha	marwaha	PROPN
ajlm-823	158	12	n.	n.	ADJ
ajlm-823	158	13	phenotype	phenotype	NOUN
ajlm-823	158	14	frequencies	frequency	NOUN
ajlm-823	158	15	of	of	ADP
ajlm-823	158	16	blood	blood	NOUN
ajlm-823	158	17	group	group	NOUN
ajlm-823	158	18	systems	system	NOUN
ajlm-823	158	19	(	(	PUNCT
ajlm-823	158	20	rh	rh	PROPN
ajlm-823	158	21	,	,	PUNCT
ajlm-823	158	22	kell	kell	PROPN
ajlm-823	158	23	,	,	PUNCT
ajlm-823	158	24	kidd	kidd	PROPN
ajlm-823	158	25	,	,	PUNCT
ajlm-823	158	26	duffy	duffy	PROPN
ajlm-823	158	27	,	,	PUNCT
ajlm-823	158	28	mns	mns	PROPN
ajlm-823	158	29	,	,	PUNCT
ajlm-823	158	30	p	p	X
ajlm-823	158	31	,	,	PUNCT
ajlm-823	158	32	lewis	lewis	PROPN
ajlm-823	158	33	,	,	PUNCT
ajlm-823	158	34	and	and	CCONJ
ajlm-823	158	35	lutheran	lutheran	NOUN
ajlm-823	158	36	)	)	PUNCT
ajlm-823	158	37	in	in	ADP
ajlm-823	158	38	north	north	NOUN
ajlm-823	158	39	indian	indian	ADJ
ajlm-823	158	40	blood	blood	NOUN
ajlm-823	158	41	donors	donor	NOUN
ajlm-823	158	42	.	.	PUNCT
ajlm-823	159	1	transfus	transfus	PROPN
ajlm-823	159	2	apher	apher	PROPN
ajlm-823	159	3	sci	sci	PROPN
ajlm-823	159	4	.	.	PROPN
ajlm-823	160	1	2010	2010	NUM
ajlm-823	160	2	aug	aug	PROPN
ajlm-823	160	3	1;43(1):17–22	1;43(1):17–22	NUM
ajlm-823	160	4	.	.	PUNCT
ajlm-823	161	1	https://doi.org/10.1016/j.transci.2010.05.006	https://doi.org/10.1016/j.transci.2010.05.006	PROPN